

# **ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ**

**ΒΑΣΙΛΗ Α. ΓΕΩΡΓΟΥΛΙΑ**  
**ΚΑΘΗΓΗΤΗ ΠΑΘΟΛΟΓΙΑΣ-ΟΓΚΟΛΟΓΙΑΣ**  
**ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΚΡΗΤΗΣ**

**Ιούλιος 2014**

**ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ**

**Όνομα:** Βασίλης Γεωργούλιας  
**Ημερομηνία γέννησης:** 27/11/1947, Αθήνα  
**Δ/ση κατοικίας:** Μαγνησίας 12 και Ατλαντίδος, Μασταμπάς,  
 Ηράκλειο Κρήτης (2810-250880)  
**Δ/ση εργασίας:** Πανεπιστήμιο Κρήτης,  
 Σχολή Επιστημών Υγείας  
 Τμήμα Ιατρικής  
 Τ.Θ. 2208, Τ.Κ. 71003 Ηράκλειο, Κρήτης  
 τηλ.: (2810) 394573, 394911  
 Fax: (2810) 394914  
 E-mail: [georgoul@med.uoc.gr](mailto:georgoul@med.uoc.gr), [georgulv@otenet.gr](mailto:georgulv@otenet.gr)

**I. ΣΤΑΔΙΟΔΡΟΜΙΑ**

**1965-1971:** Ιατρική Σχολή Παν/μίου Αθηνών.  
**1972-1974:** Στρατιωτική θητεία.  
**1973-1974:** Εσωτ. άμισθος βοηθός (Β' Παθολ. Κλινική ΓΚΝΑ, Δ/ντής: Α. Μπίλλης).  
**1974-1976:** Υπηρεσία Υπαίθρου.  
**1976-1977:** Εσωτ. βοηθός (Πνευμονολογική Κλινική Νοσοκομείου Τσαγγάρη, Δ/ντής: Δ. Καμαρούλιας).  
**1977-1980:** Εσωτ. βοηθός (Α' Παθολογ. Κλινική Παν/μίου Αθηνών, Λαϊκό Νοσοκομείο, Δ/ντής: Καθ. Φ. Φέσσας).  
**1980-1985:** Assistant etranger-boursier (Service de Maladies Sanguines et Tumorales de l' Université de Paris XI, Hopital Paul Brousse, Γαλλία, Δ/ντής: Καθ. G. Mathe).  
**1985:** Charge de Recherche 1ere Classe (Institut National de Sante et de la Recherche Medicale, INSERM). Σε μακροχρόνια άδεια άνευ αποδοχών από το 1990.  
**1985-1990:** Επίκουρος Καθηγητής Παθολογίας-Ογκολογίας Παν/μίου Κρήτης.  
**Μάϊος 1990:** Αναπληρωτής Καθηγητής Παθολογίας-Ογκολογίας Παν/μίου Κρήτης.  
**Φεβρουάριος 1998:** Καθηγητής Παθολογίας-Ογκολογίας.  
**Ιανουάριος 1991 -** Δ/ντής Πανεπιστημιακής Παθολογικής-Ογκολογικής Κλινικής  
**Μαΐος 2014:** Πανεπιστημιακού Νοσοκομείου Ηρακλείου.

**Αύγουστος 2007-**

**Αύγουστος 2011-** Αναπληρωτής Πρόεδρος Ιατρικής Σχολής Πανεπιστημίου Κρήτης

## **II. ΔΙΠΛΩΜΑΤΑ**

- 1971:** Πτυχίο Ιατρικής Σχολής Παν/μίου Αθηνών.
- 1981:** Διδακτορική διατριβή, Ιατρική Σχολή Πανεπιστημίου Αθηνών.
- 1982:** Certificat d' Etudes Superieures de Biologie Humaine, Mention: Radiobiologie (Universitte Paris XI).
- 1982:** Certificat d' Etudes Superieures de Biologie Humaine, Mention: Cancerologie Generale et Experimentale (Universitte Paris XI).
- 1982:** Certificat d' Etudes Superieures de Biologie Humaine: Hematologie (Universitte Paris VII).
- 1983:** Certificat d' Etudes Superieures de Cancerologie Clinique (Universttte Paris XI).
- 1983:** Attestation d' Etudes Approfondies (AEA) de Cancerologie Experimentale: Immunologie du Cancer et des Transplantations (Universitte Paris XI).
- 1984:** Diplome d' Etudes et de Recherche en Biologie Humaine: Immunologie du Cancer et des Transplantations (Universite Paris XI).

## **III. ΤΙΤΛΟΙ**

- 1984:** Επίκουρος Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικό Τμήμα Πανεπιστημίου Κρήτης,
- 1985:** Maitre es Sciences Medicales, Ιατρική Σχολή Παν/μίου Paris XI,
- 1986:** Charge de Recherche, 1ere Classe, Institut de Sante et de Recherche Medicale, (INSERM ) (Μόνιμη θέση, μετά από Εθνικό διαγωνισμό),
- 1990:** Αναπληρωτής Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικό Τμήμα Πανεπιστημίου Κρήτης.
- 1991:** Διευθυντής Παθολογικής-Ογκολογικής Κλινικής, Παν/κό Νοσοκομείο Ηρακλείου.
- 1998:** Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικό Τμήμα Πανεπιστημίου Κρήτης.
- 2007-2011:** Αναπληρωτής Πρόεδρος Ιατρικού Τμήματος Παν/μίου Κρήτης

## **IV. ΥΠΟΤΡΟΦΙΕΣ-ΔΙΑΚΡΙΣΕΙΣ**

1. Υποτροφία της Γαλλικής Κυβερνήσεως για μετεκπαίδευση στην Ογκολογία: 1980-1983 (3 χρόνια).

2. Υποτροφία της Association de la Recherche contre le Cancer (ARC): 1983-1984 (12 μήνες).
3. Υποτροφία της Ligue National contre le Cancer: 1983-1984 (6 μήνες).
4. Υποτροφία του Γαλλικού Υπουργείου Έρευνας και Συνεργασίας: 1984-1985 (6 μήνες, στο πλαίσιο Διακρατικού Προγράμματος Ελληνο-Γαλλικής Συνεργασίας).

#### **V. ΔΙΔΑΚΤΟΡΙΚΕΣ ΔΙΑΤΡΙΒΕΣ (Επιβλέπων Καθηγητής):**

##### **A) Έχουν ολοκληρωθεί και υποστηριχθεί**

- 1) B. Τσιλιβάκος: Χαρακτηρισμός του υποδοχέα της IL-2 στα κύτταρα της ΧΛΛ
- 2) N. Μαλλιάρáκη: Ιολογικές και μοριακές ενδείξεις λανθάνουσας HIV μόλυνσης σε άτομα με αδιευκρίνιστο Western Blot
- 3) M. Περράκη: Μηχανισμοί πολλαπλασιασμού νεοπλασματικών κυττάρων ΟΛΛ
- 4) A. Σταθοπούλου: Συγκριτική μελέτη του mRNA της κυτταροκερατίνης-19, της maspin και του CEA στο αίμα ασθενών με καρκίνο του μαστού και διερεύνηση των μεταβολών τους κατά τη διάρκεια της χημειοθεραπείας ή της ορμονοθεραπείας
- 5) E. Σάρρα: Μελέτη της δράσης των αιμοποιητικών αυξητικών παραγόντων GM-CSF και G-CSF στο λεμφοκυτταρικό σύστημα κατά την φάση της μυελικής ανάπλασης
- 6) A. Κωτσάκης: Προοπτική μελέτη της δράσης αντινεοπλασματικών φαρμάκων στο Τα-λεμφοκυτταρικό σύστημα
- 7) N. Ξενίδης: Μελέτη της επίδρασης της χημειοθεραπείας και ορμονοθεραπείας στην ανίχνευση του mRNA της κυτταροκερατίνης 19 στο αίμα και τον μυελό των οστών ασθενών με πρώιμο καρκίνο του μαστού
- 8) Π. Σωτηροπούλου: Παραγωγή αντιγονοειδικών T. λεμφοκυττάρων κλώνων ενάντια σε περπιττidia ογκοπρωτεϊνών με μεγάλη συχνότητα εμφάνισης σε ποικίλες μορφές καρκίνου
- 9) Γ. Καλλέργη: Μελέτη των μεταβολών της δυναμικής ισορροπίας της ακτίνης
- 10) A. Κουλουμπίνης: Μορφές καρδιοτοξικότητας σε ογκολογικούς ασθενείς υπό χημειοθεραπεία και η σχέση τους με την ανίχνευση κυτοκινών και αποπτωτικών ογκογονιδίων
- 11) Δ. Καλμαντή: Αγγειογένεση σε αιματολογικές κακοήθειες και συμπαγείς όγκους
- 12) A. Ακουμιανάκη: Ρόλος της Τουμπουλίνης και επίδραση ταξάνων και παραγώγων τους στην οργάνωση, λειτουργικότητα και δυναμική του πυρηνικού φακέλου

- 13) Ι. Μπουκοβίνας: Αγγειογενετικοί μηχανισμοί και συγκριτική μελέτη της αντοχής του μη-μικροκυτταρικού καρκίνου του πνεύμονα σε δύο σχήματα χημειοθεραπείας με Docetaxel/Cis-platin vs Docetaxel/Gemcitabine
- 14) Θ. Χατζιδάκη: Ο ρόλος της χημειοθεραπείας διάσωσης σε ασθενείς με τοπικά εκτεταμένο και μεταστατικό μη-μικροκυτταρικό καρκίνο του πνεύμονος. Μελέτη των παραγόντων που επηρεάζουν την επιβίωση των ασθενών μετά τη χημειοθεραπεία 1<sup>ης</sup> γραμμής
- 15) Β. Μποζιονέλου: Μελέτη της επίδρασης του Herceptin (trastuzumab) σε κυκλοφορούντα CK-19 mRNA θετικά κύτταρα, στο αίμα και το μυελό των οστών, ασθενών με καρκίνο του μαστού
- 16) Ν. Βαρδάκης: Μελέτη της προγνωστικής σημασίας της ανίχνευσης μικρομεταστατικής νόσου στο αίμα και τον μυελό των οστών σε ασθενείς με καρκίνο του παχέος εντέρου σταδίου B2 και C κατά Astler-Coller
- 17) Δ. Παπαδάτος-Πατσός: Εκτίμηση μοριακών παραγόντων και συσχέτιση τους με την ανταπόκριση στην θεραπεία και την επιβίωση σε ασθενείς με μεταστατικό καρκίνο του παχέος εντέρου που έχουν λάβει θεραπεία πρώτης γραμμής με 5FU/LOHP/CPT-11
- 18) Α. Βαλαχής: Μετα-ανάλυση τυχαιοποιημένων κλινικών μελετών χημειοθεραπείας, ακτινοθεραπείας και ορμονοθεραπείας στον καρκίνο του μαστού
- 19) Ν. Ανδρουλάκης: Μελέτη του mRNA της κυτταροκερατίνης 19 (K-19) στο αίμα και το μυελό των οστών ασθενών με μεταστατικό καρκίνο του μαστού: συσχετίσεις με την πορεία της νόσου και την ευασθησία της στη χημειοθεραπεία
- 20) Ε. Σαλούστρος: Αξιολόγηση της προγνωστικής αξίας των κυκλοφορούντων καρκινικών κυττάρων κατά τη διάρκεια παρακολούθησης ασθενών με πρώιμο καρκίνο μαστού.
- 21) Αρ. Καλυκάκη: Ανίχνευση μεταλλάξεων του EGFR και K-RAS σε ασθενείς με MMKΠ και διερεύνηση της αξίας τους ως προβλεπτικό παράγοντα ανταπόκρισης στη θεραπεία
- 22) Ν. Καραχάλιου: Μελέτη της προγνωστικής ή/και προβλεπτικής αξίας των γονιδίων ERCC1, BRCA1, ATR7B, TOP1, TOP2A και TOP2B στην έκβαση των ασθενών με μικροκυτταρικό καρκίνο του πνεύμονα.

**B) Έχουν ολοκληρωθεί και είναι στη φάση της συγγραφής**

- 1) Λ. Βαμβακάς: Μελέτη φάσης II χορήγησης του Irinotecan (CPT-11) σε ασθενείς με μεταστατικό καρκίνο του παχέος εντέρου σε μονοθεραπεία ή σε συνδυασμό με 5-fluorouracil
- 2) Α. Τσαρουχά: Ενδονουκλεάσες-απόπτωση και συγκριτική μελέτη της αντοχής του μη-μικροκυτταρικού καρκίνου του πνεύμονα σε δύο σχήματα χημειοθεραπείας με Docetaxel/Cis-platin vs Docetaxel/Gemcitabine

### **Γ) Υπό εξέλιξη**

- 1) Κ. Καλμπάκης: Προγνωστική αξία της εκτίμησης της αγγειογένεσης σε πρωτοπαθή καρκινώματα του μαστού και σε διηθημένους μασχαλιαίους λεμφαδένες (συνεχίζεται το πειραματικό σκέλος).
- 2) Ν. Μπουντούρογλου: Η σχέση της χημειοθεραπείας με τη λεμφαγγειογένεση την αγγειακή διήθηση στον πρωτοπαθή όγκο και την ανίχνευση της κερατίνης 20 του καρκινοεμβρικού αντιγόνου και του ενεργοποιητή του πλασμινογόνου του τύπου της ουροκινάσης με καρκίνο του παχέος εντέρου (στη φάση της δημοσίευσης άρθρου)
- 3) Γ. Μηλάκη: Ο ρόλος της χημειοθεραπείας διάσωσης σε ασθενείς με τοπικά εκτεταμένο και μεταστατικό μη-μικροκυτταρικό καρκίνο του πνεύμονος. Μελέτη των παραγόντων που επηρεάζουν την επιβίωση των ασθενών μετά τη χημειοθεραπεία 1<sup>ης</sup> γραμμής (συνεχίζεται το πειραματικό σκέλος).
- 4) Α. Καραμπεάζης: Πολυδιάστατη γηριατρική αξιολόγηση και εκτίμηση ποιότητας ζωής σε ηλικιωμένους ασθενείς με ανεγχείρητο μη-μικροκυτταρικό καρκίνο πνεύμονα που υποβάλλονται σε χημειοθεραπεία (στη φάση της δημοσίευσης άρθρου)
- 5) Α. Πρινάρη: Μελέτη παραγόντων που επηρεάζουν την αποτελεσματικότητα, την έκβαση και την ποιότητα ζωής ηλικιωμένων ασθενών που υποβάλλονται σε θεραπεία για μεταστατικό καρκίνο παχέος εντέρου (συνεχίζεται το πειραματικό σκέλος).
- 6) Π. Παπακοτούλας: Μελέτη του Thyroid Transcription Factor 1 (TTF 1) σε ασθενείς με μη μικροκυτταρικό καρκίνο του πνεύμονα (συνεχίζεται το πειραματικό σκέλος).
- 7) Ε. Λαγουδάκη: Μελέτη των γενετικών μεταβολών του γονιδίου LKB1 και συσχέτιση τους με την διήθηση των επιχώριων και μεσοθωρακικών λεμφαδένων σε χειρουργήσιμο μη μικροκυτταρικό καρκίνωμα του πνεύμονα (συνεχίζεται το πειραματικό σκέλος).

- 8) Μ. Παπαδάκη: Φαινοτυπικός μοριακός χαρακτηρισμός των κυκλοφορούντων καρκινικών κυττάρων σε αίμα ασθενών με καρκίνο του μαστού.
- 9) Γ. Σφακιωτάκη: Φαρμακογενομική ανάλυση στον πρωτοπαθή όγκο ασθενών οι οποίοι λαμβάνουν χημειοθεραπεία με βάση την oxaliplatin για μεταστατικό καρκίνο παχέος εντέρου (συνεχίζεται το πειραματικό σκέλος).
- 10) Γ. Ιωαννίδης: Διερεύνηση του προβλεπτικού και προγνωστικού ρόλου της έκφρασης των γονιδίων *BRCA1*, *RRM1*, *RRM2*, *hENT1*, *dCK* και *CDA* στον προχωρημένο μη-μικροκυτταρικό καρκίνο του πνεύμονα (συνεχίζεται το πειραματικό σκέλος).
- 11) Ζ. Ζαφειρίου: Διερεύνηση των μεταβολών των ανοσο-κατασταλτικών κυττάρων στο αίμα ασθενών με μεταστατικά νεοπλάσματα που λαμβάνουν θεραπεία 1ης γραμμής με βάση τον αντι-αγγειογενετικό παράγοντα bevacizumab.
- 12) Α. Ματίκας: Ανίχνευση RAS family και BRAF μεταλλάξεων σε κυκλοφορούντα καρκινικά κύτταρα σε ασθενείς με μεταστατικό ορθοκολικό καρκίνο με ή χωρίς μετάλλαξη στον πρωτοπαθή όγκο, οι οποίοι υποβάλλονται σε θεραπεία με βιολογικούς παράγοντες.

## VI. ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΕΙΩΝ

### Εθνικές Εταιρείες

1. Ελληνική Εταιρεία Ιατρικών Σπουδών.
2. Ελληνική Εταιρεία Χημειοθεραπείας.
3. Ελληνική Ανοσολογική Εταιρεία.
4. Ελληνική Αιματολογική Εταιρεία.
5. Εταιρεία Ογκολόγων-Παθολόγων Ελλάδος (ΕΟΠΕ).
6. Ελληνική Εταιρεία Μελέτης του AIDS και Σεξουαλικά Μεταδιδόμενων Νοσημάτων.
7. Ελληνική Αντικαρκινική Εταιρεία.

### Διεθνείς Εταιρείες

1. New York Academy of Sciences.
2. International Society of Experimental Hematology
3. American Society of Clinical Oncology (ASCO).
4. International Society of AIDS.
5. European Society of Medical Oncology (ESMO).
6. International Oncology Foundation (Μέλος του 20μελούς Advisory Board)

7. American Association of Cancer Research (AACR)
8. International Association for Lung Cancer Studies (IALSC)

## **VII. Συμμετοχή σε Διεθνείς Ερευνητικές Ομάδες**

1. European Organization for Research and Treatment of Cancer (EORTC)
2. European Thoracic Platform (ETOP)
3. Breast International Group (BIG)
4. International Cancer Collaboration Group (ICCG)
5. Breast Cancer International Research Group (BCIRG)
6. Ad hoc συνεργασία με διάφορες ερευνητικές ομάδες στο πλαίσιο διεξαγωγής πολυκεντρικών κλινικών μελετών.

## **VII. ΜΕΙΖΟΝΕΣ ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ**

- 1987:** Αναπτυξιακό Πρόγραμμα ΥΕΠΘ (Υπεύθυνοι: Β. Γεωργούλιας, Χ. Στουρνάρας, Ι. Παπαματθαϊάκης): 95.000.000 δρχ.
- 1991:** Περιφερειακό Πρόγραμμα Ανάπτυξης ΕΟΚ (ΣΠΑ): (Υπεύθυνοι: Β. Γεωργούλιας, Χ. Στουρνάρας, Α. Γραβάνης): 65.000.000 δρχ.
- 1993:** Πρόγραμμα STRIDE (ΕΟΚ) (Υπεύθυνος Π. Κορδοπάτης, Φαρμακευτικό Πάτρας, Υπεύθυνοι για Κρήτη Β. Γεωργούλιας, Χ. Στουρνάρας, Α. Γραββάνης): 12.000.000 δρχ.
- 1991-93:** Συμμετοχή στο Πρόγραμμα Ευρωπαϊκής Κοινότητας διατεθέν μέσω της Περιφέρειας Κρήτης για την «Εκπαίδευση επιστημονικού παραϊατρικού προσωπικού σε υψηλήΒιοϊατρική Τεχνολογία» (Συντονιστής Χ. Στουρνάρας): 84.000.000 δρχ.
- 1994:** Γενική Γραμματεία Έρευνας και Τεχνολογίας: 6.000.000 δρχ.
- 1995:** Υποτροφία Ελληνικής Ανοσολογικής Εταιρείας για υποστήριξη εκπόνησης διδακτορικής διατριβής: 1.500.000 δρχ.
- 1995:** Κέντρο Ελέγχου Ειδικών Λοιμώξεων: Χρηματοδότηση ερευνητικών προτάσεων: 10.000.000 δρχ.
- 2000:** Πρόγραμμα Γενικής Γραμματείας Έρευνας και Τεχνολογίας για την ανάπτυξη τεχνολογίας ανοσοθεραπείας και μεταμόσχευσης στον καρκίνο (Συντονιστές Ν. Ζούμπος και Μ. Παπαμιχαήλ): 30.000.000 δρχ.
- 2003:** Εταιρεία Παθολόγων Ογκολόγων Ελλάδος (ΕΟΠΕ) για υποστήριξη εκπόνησης διδακτορικής διατριβής: 3.000.000 δρχ



- 2003:** Πρόγραμμα ΕΠΑΝ, Γενικής Γραμματείας Έρευνας και Τεχνολογίας  
«Φαρμακογονιδιωματική και πρωτεϊνική Μηχανική της S-Γλουταθειόνης (GTS) για την μελέτη της ανθεκτικότητας των όγκων έναντι της Cisplatin και την στοχευμένη χημειοθεραπεία των συμπαγών όγκων» (Συντονιστής: Β. Γεωργούλιας, σε συνεργασία με την Φαρμακοβιομηχανία): 300.000.000 δρχ.
- 2003:** Πρόγραμμα Πυθαγόρας (κωδ. Έργου: 89185). Τίτλος: «Ενίσχυση ερευνητικών ομάδων στο Πανεπιστήμιο Κρήτης» (Υπεύθυνος Χ. Στουρνάρας, Συμμετέχοντες: Β. Γεωργούλιας, Δ. Μαυρουδής, Α. Γραββάνης, Γ. Καλλέργη): 170.000€.
- 2003:** Πρόγραμμα ΓΓΕΤ (κωδ. Έργου 03ΕΔ271). Τίτλος: «Μοριακή διάγνωση της μικρομεταστατικής νόσου στον καρκίνο του μαστού με αξιοποίηση της τεχνολογίας των ηλεκτρονικών μικροσυστοιχιών DNA. (Συντονιστής: Ε. Λιανίδου, Συμμετέχοντες: Ε. Καναβάκης, β. Γεωργούλιας, Δ. Σανούδου): 138.480€.

Επίσης, ερευνητικά προγράμματα μου έχουν χρηματοδοτηθεί με μικρότερα ποσά από τον Ειδικό Λογαριασμό του Πανεπιστημίου Κρήτης και το ΚΕΣΥ κατά τα έτη 1985-σήμερα.

### **VIII. ΜΕΙΖΟΝΕΣ ΕΡΕΥΝΗΤΙΚΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ**

- α.** Μελέτη νέων αντινεοπλασματικών φαρμάκων και των συνδυασμών τους στην αντιμετώπιση του καρκίνου του πνεύμονος, μαστού, ουροθηλίου, παχέος εντέρου και παγκρέατος.
- β.** Πρόγραμμα διερεύνησης των μηχανισμών ευαισθησίας και αντίστασης νεοπλασματικών κυττάρων ασθενών με καρκίνο του πνεύμονα, του στομάχου και της ωοθήκης στα χημειοθεραπευτικά φάρμακα.
- γ.** Μελέτη της επίπτωσης και της θνησιμότητας από καρκίνο στην Κρήτη.
- δ.** Εκτίμηση του ρόλου της αγγειογένεσης στην φαρμακευτική ανταπόκριση και την θνησιμότητα από διάφορα νεοπλάσματα.
- ε.** Μελέτη και χαρακτηρισμός των μικρομεταστατικών κυττάρων στο αίμα και τον μυελό των οστών ασθενών με καρκίνο του μαστού, παχέος εντέρου και μη-μικροκυτταρικού καρκίνου του πνεύμονος.
- στ.** Διερεύνηση του ρόλου των μεταλλάξεων διαφόρων γονιδίων στη καρκινογένεση και στην ανταπόκριση της θεραπείας σε ασθενείς με Μη-Μικροκυτταρικό Καρκίνο του Πνεύμονα και του καρκίνου παχέος εντέρου.



**ΙΧ. ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ (αναφέρονται μόνο οι πλήρεις δημοσιεύσεις σε επιστημονικά περιοδικά με κριτές).**

**ΕΛΛΗΝΙΚΟΣ ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΤΥΠΟΣ**

1. Δ. Καμαρούλιας, Β. Γεωργούλιας: Πρωτοπαθές αδενοκαρκίνωμα του πνεύμονος αναπτυχθέν 10 έτη μετά την ριζική αφαίρεση δικτυοσαρκώματος του στομάχου. Ιατρική 33: 539, 1978.
2. Β. Γεωργούλιας: Πολλαπλοί πρωτοπαθείς όγκοι των πνευμόνων. Ιατρική 34: 395, 1978 (άρθρο ανασκόπησης).
3. Δ. Καμαρούλιας, Ι. Αναγνωστάκης, Κ. Παπαδήμας, Ι. Αντωνάκος, Β. Γεωργούλιας: Η συμπεριφορά των ασθματικών ασθενών εις τα αναλγητικά φάρμακα. Αποτελέσματα εκ της χορηγήσεως 10 αναλγητικών φαρμάκων εις 50 ασθματικούς ασθενείς. Σωτηρία 3: 79, 1979.
4. Β. Γεωργούλιας, Κ. Τέντας, Ν. Παπανικολάου, Λ. Νακοπούλου, Δ. Λουκόπουλος, Φ. Φέσσας: Πολλαπλά πρωτοπαθή νεοπλάσματα. Ιπποκράτης 8: 319, 1980 (άρθρο ανασκόπησης).
5. Β. Γεωργούλιας, Π. Ρούσσου, Β. Γολεμάτης, Δ. Λουκόπουλος, Φ. Φέσσας: Αδενοκαρκίνωμα του παγκρέατος και βαρεία ηπατική ανεπάρκεια σε ασθενή με λευχαιμία από «τριχωτά» κύτταρα. Ιατρική 38: 63, 1980.
6. Π. Ρούσσου, Β. Γεωργούλιας, Χ. Κιττάς, Δ. Λουκόπουλος, Φ. Φέσσας: Λεμφωματοειδής κοκκιωμάτωση: Συνδυασμός με υπερηωσινοφιλικό σύνδρομο και μετάπτωση σε μη-Hodgkin λέμφωμα. Ιατρική 40: 303, 1981.
7. Β. Γεωργούλιας, Δ. Λουκόπουλος, Φ. Φέσσας: Κύτταρα F στον Ελληνικό πληθυσμό. Μελέτη με ανοσοφθορισμό. Ιατρική 41: 390, 1982.
8. Β. Γεωργούλιας, Y.Lunardi-Iskandar, G.Mathe, C. Jasmin: Καλλιέργεια μυελοβλαστών σε αρρώστους με οξεία μυελοβλαστική λευχαιμία και χρόνια μυελογενή λευχαιμία σε βλαστική κρίση. Ιατρική 47: 241, 1985.
9. Β. Γεωργούλιας, Y.Lunardi-Iskandar, G.Mathe, C.Jasmin: In vitro χημειοευαισθησία των κλωνογόνων λευχαιμικών μυελοβλαστών (CFU-ML) σε αντικαρκινικά φάρμακα και συσχέτιση με την κλινική απάντηση. Ιατρική 48: 41, 1985.
10. Δ. Τσατσάκη, Μ. Θεοδοροπούλου, Α. Κατρακάζου, Π. Φουντούλη, Α. Καρβέλα-Αγγελάκη, Γ. Κόμης, Ε. Μαλλιάρáκη-Πινετίδου, Β. Γεωργούλιας: Προβληματισμός στην διάγνωση της μόλυνσης με τον ιό της ανθρώπινης ανοσοανεπάρκειας (HIV-1). Ιατρική 56: 61, 1989.

11. Δ. Καρβέλα-Αγγελάκη, Π. Φουντούλη, Α. Κατρακάζου, Δ. Τσατσάκη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Περίπτωση HIV-2 μονομόλυνσης στην Ελλάδα. *Ιατρική* 56: 476, 1989.
12. Μ. Θεοδοροπούλου, Ν. Μαλλιαράκη, Ε. Σπανάκης, Α. Καρβέλα-Αγγελάκη, Π. Φουντούλη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Ενδείξεις λανθάνουσας HIV-1 μόλυνσης σε άτομα που παρουσιάζουν αντισώματα έναντι των πρωτεϊνών gag του ιού. *Ιατρική* 57: 602, 1990.
13. Μ. Περράκη, Μ. Θεοδοροπούλου, Ν. Μαλλιαράκη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Αυξημένα επίπεδα διαλυτού υποδοχέα IL2 (sIL-2Ra) σε οροθετικούς για HIV ασθενείς: Κυτταρική παραγωγή και κλινικές συσχετίσεις. *Ιατρική* 64: 154, 1993.
14. Ι. Ματαλιωτάκης, Β. Γεωργούλιας, Δ. Σταύρου, Γ. Βλάσσης, Ε. Κουμαντάκης: Η επίδραση του Danazol στα επίπεδα του διαλυτού υποδοχέα της Ιντερλευκίνης 2 (sIL-2R) σε γυναίκες με ενδομητρίωση. *Εφηβ. Γυν. Αναπλ. Εμμην.* 5: 212, 1993.
15. Μ. Σμυρλάκη-Θεοδοροπούλου, Ν. Μαλλιαράκη, Δ. Τσατσάκη, Σ. Κωτσάκη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Κλινική ετερογένεια της λοιμώξεως με τον HIV: Ενδείξεις από την in vitro απομόνωση του ιού και τον γονιδιακό πολλαπλασιασμό. *Ιατρική* 65: 160, 1994.
16. Ι. Ματαλιωτάκης, Ε. Κουμαντάκης, Μ. Νεονάκη, Β. Γεωργούλιας: Προσδιορισμός επιπέδων του διαλυτού υποδοχέα της Ιντερλευκίνης 2 (sIL-2R) στον ορό γυναικών με φυσιολογική και παθολογική εξέλιξη της εγκυμοσύνης. *Αρχ. Ελλην. Ιατρ.* 11: 21, 1994.
17. Δ. Τσατσάκη, Σ. Μπακογιώργου, Π. Φουντούλη, Σ. Κωτσάκη, Μ. Θεοδοροπούλου, Ν. Μαλλιαράκη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Ανίχνευση αντισωμάτων έναντι πεπτιδίων της πρωτεΐνης nef του HIV σε άτομα με HIV μόλυνση και σε ορούς ατόμων με αδιευκρίνιστο Western Blot. *Ιατρική* 66: 35, 1994.
18. Β. Τσιλιβάκος, Σ. Κακολύρης, Π. Ηλιάκης, Μ. Περράκη, Β. Γεωργούλιας: Παρουσία υποδοχέων Ιντερλευκίνης 2 αυξημένης συγγενείας σε νεοπλασματικά κύτταρα χρόνιας λεμφογενούς λευχαιμίας. *Ιατρική* 67: 65-71, 1995.
19. Ι. Βλαχονικολής, Β. Γεωργούλιας, Δ. Φιλαλήθης: Θνησιμότητα από κακοήθη νεοπλάσματα στην Κρήτη, 1992. *Ιατρική* 69: 291-302, 1996.
20. Σ. Κακολύρης, Γ. Σαμώνης, Π. Τολούδης, Σ. Αγγελάκη, Κ. Καλμπάκης, Ε. Κυρλάκη, Α. Ξυλούρης, Γ. Χαλκιαδάκης, Ι. Βλαχονικολής, Β. Γεωργούλιας: Αντιμετώπιση του μη-μικροκυτταρικού καρκίνου του πνεύμονα με μακροχρόνια χορήγηση Ετοποσίδης από το στόμα. *Ιατρική* 69: 285-290, 1996.

21. Π. Φουντούλη, Ν. Μαλλιαράκη, Μ. Θεοδοροπούλου, Δ. Τσατσάκη, Κ. Λιάκου-Μπιμπάκη, Σ. Κωτσάκη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Ειδικότητα των anti-gag αντισωμάτων που διαπιστώνονται σε άτομα «χαμηλού κινδύνου» για HIV λοίμωξη με αδιευκρίνιστο Western Blot. Ιατρική 70 (4): 337-342, 1996.
22. Παπαδάκη, Κ. Καλμπάκης, Ε. Σάρρα, Ι. Σουγκλάκος, Χ. Κουρούσης, Σ. Κακολύρης, Π. Χέρας, Α. Κωτσάκης, Ε. Στεφανάκης, Λ. Βαμβακάς, Β. Γεωργούλιας: Μεταβολές λεμφοκυτταρικών πληθυσμών κατά τη φάση της απλασίας και της μυελικής αναγέννησης σε ασθενείς με συμπαγή νεοπλάσματα υπό χημειοθεραπεία. Βήμα Ελλην. Ογκολογ. 1: 19, 1997.
23. Σ. Κακολύρης, Χ. Χριστοφυλλάκης, Κ. Καλμπάκης, Μ. Τσαγκουρνισάκης, Α. Καλογεράκης, Γ. Σαμώνης, Β. Γεωργούλιας: Μεταναστευτική πολλαπλή μονονευρίτις σαν πρώτη εκδήλωση Non-Hodgkin's λεμφώματος υψηλής κακοήθειας, Β-τύπου. Ιατρική 71: 602-605, 1997.
24. Π. Ματαλλιωτάκης Ι., Νεονάκη Μ., Χασάν Ε., Ζολινδάκη Α., Γεωργούλιας Β., Κουμαντάκης Ε: Μελέτη επιπέδων του SCD8 στον ορό εγκύων γυναικών. Ελλην. Μαιευτ. Γυναικ. 9: 49-53, 1997.
25. Σ. Κακολύρης, Χ. Κουρούσης, Κ. Καλμπάκης, Σ. Αγγελάκη, Π. Καναβάρος, Δ. Στεφανάκη, Β. Γεωργούλιας: Συμπύεση νωτιαίου μυελού σαν κύρια εκδήλωση εμφάνισης της νόσο Hodgkin's. Βήμα Κλινικής Ογκολογίας 2 (1): 68-72, 1999.
26. Ι. Βλαχονικολής, Ι. Σουγκλάκος, Ε. Μαυρονανωλάκης, Β. Γεωργούλιας: Επιδημιολογία του καρκίνου στην Κρήτη: Θνησιμότητα 1992-1993.
27. Α. Πάλλης, Δ. Μαυρουδής, Β. Μποζιονέλου, Ν. Ξενίδης, Γ. Μηλάκη, Ν. Βαρδάκης, Β. Γεωργούλιας: Χορήγηση ZD1839, ενός αναστολέα της τυροσινικής κινάσης του επιδερμικού αυξητικού παράγοντα, ως θεραπεία διάσωσης σε ασθενείς με εκτεταμένο μη-μικροκυτταρικό καρκίνο του πνεύμονα. Η εμπειρία της Ογκολογικής Κλινικής τους Πανεπιστημιακού Νοσοκομείου Ηρακελίου. Βήμα Κλινικής Ογκολογίας 1(4): 208-219, 2002.
28. Β. Μποζιονέλου, Σ. Αγγελάκη, Χ. Κουρούσης, Α. Αρδαβάνης, Κ. Καλμπάκης, Κ. Μαλάς, Ν. Μαλάμος, Α. Αλεξόπουλος, Ε. Τσελεπατιώτης, Β. Γεωργούλιας: Χορήγηση του συνδυασμού γεμισιταμπίνης και ιρινοτεκάνης σε ασθενείς με μεταστατικό καρκίνο του μαστού που έχουν λάβει θεραπεία με ταξάνες και ανθρωκυκλίνιες: Μια πολυκεντρική μελέτη φάσης II. Βήμα Κλινικής Ογκολογίας 2 (3):272-278, 2003.

29. Ζ. Σαριδάκη, Ε. Κοντοπόδης, Ε. Σαλούστρος, Σ. Αγγελάκη, Γ. Σουγκλάκος, Β. Γεωργούλιας, Δ. Μαυρουδής: Η επίδραση των γονιδιακών πολυμορφισμών στη χρήση μοριακά στοχευμένων αντι-νεοπλασματικών παραγόντων. Βήμα Κλινικής Ογκολογίας 7(2): 156-166, 2008,
30. Κ. Κωτσάκης, Β. Γεωργούλιας: KRAS μεταλλάξεις και θεραπευτικό αποτέλεσμα: Νεότερα δεδομένα. Βήμα Κλινικής Ογκολογίας 8(1-2): 55-61, 2009.
31. Α.Γ. Πάλλης, Λ. Βαμβακάς, Β. Γεωργούλιας: Γηριατρική Ογκολογία: Ιδιαιτερότητες και προκλήσεις. Βήμα Κλινικής Ογκολογίας 8(3-4): 157-165, 2009.
32. Α.Γ. Πάλλης, Λ. Βαμβακάς, Α. Καραμπεάζης, Β. Γεωργούλιας: Θεραπεία του εκτεταμένου/μεταστατικού μη-μικροκυτταρικού καρκίνου του πνεύμονα σε ηλικιωμένους ασθενείς. Βήμα Κλινικής Ογκολογίας 8(1-2): 63-71, 2009.
33. A.G. Pallis, A. Athanasiadis, S. Agelaki, X.Tsiafaki, V. Chandrinos, S. Kakolyris, G. Pavlakou, L. Vamvakas, A. Karampeazis, V. Georgoulis. Oral Vinorelbine and Gemcitabine versus Docetaxel and Gemcitabine as front-line treatment of patients with inoperable advanced and metastatic non-small-cell lung cancer (NSCLC): A multicenter randomized phase III study. Forum of Clinical Oncology, Vol 1, No 3 (2010).
34. A.G. Pallis, V. Georgoulis. Is there a new standard for 1st line treatment of older non-small-cell lung cancer patients? Forum of Clinical Oncology, Vol 1, No 3 (2010)
35. A. G. Pallis, V. Georgoulis, Ethics in medical publishing: a “burning” issue, Forum of Clinical Oncology, Vol 1, No 3 (2010).
36. A. Kalykaki, P. Papakotoulas, I. Boukovinas, N. Vardakis, V. Bozionelou, I. Varthalitis, A. Athanasiadis, A. Polyzos, A. Potamianou, D. Mavroudis, V. Georgoulis, Salvage Chemotherapy with Gemcitabine and Pegylated Liposomal Doxorubicine in Pretreated Patients with Ovarian Cancer: A Multicenter Phase II Study, Forum of Clinical Oncology, Vol 1, No 1 (2010).
37. A. Pallis, L. Vamvakas, V. Georgoulis. Targeted Treatment for Older Patients with Advanced/Metastatic Non-Small Cell Lung Cancer, Forum of Clinical Oncology, Vol 1, No 1 (2010).
38. G. Ioannidis, V. Georgoulis, I. Souglakos. Targeting VEGF- Biomarkers: A new age in personalized healthcare, Forum of Clinical Oncology, Vol 1, No 2 (2010): SPECIAL ISSUE BEVACIZUMAB
39. E. Athanasiadis, V. Georgoulis, C. Kalophonos, P. Kosmidis, V. Barbounis, A. Bamias, I. Boukovinas, D. Pectasides, E. Samantas, D. Skarlos. Consensus on the better diagnosis,

treatment and management of non-infectious pneumonitis. *Forum of Clinical Oncology* Vol 2, No 5, p37-39, 2011.

40. I. Gioulbasanis, K. Kamposioras, D. Doufexis, P. J. Vlachostergios, M. Makridou, Z. Giannousi, S. Ghosh, M. Tzereme, C. N. Papandreou, V. Georgoulis: Predictive and prognostic value of the Glasgow Prognostic Score (GPS) in Greek patients with metastatic lung cancer. *Forum of Clin Oncology* 2(1): 14-18, 2011.
41. A. Kalykaki, C. Papadimitriou, G. Aravantinos, E. Efstathiou, G. Fountzilas, A. Polyzos, C. Kouroussis, A. Ardavanis, A. Athanassiadis, E. Samantas, M. A. Dimopoulos, D. Mavroudis, V. Georgoulis, A multicenter phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin in women with advanced recurrent ovarian cancer, *Forum of Clinical Oncology*, Vol 2, No 2 (2011).
42. K. Tryfonidis, M. Rovithi, J. Souglakos, D. Mavroudis, V. Georgoulis. Thrombotic thrombocytopenic purpura in a patient with lung adenocarcinoma: A case report and literature review. *Forum of clinical Oncology* Vol 3, No 1 (2012)
43. A. Karampeazis, P. Pappas, A. Koutsopoulos, A. Kotsakis, S. Agelaki, N. Vardakis, M. Nikolaidou, M. Marselos, V. Georgoulis, D. Mavroudis. A phase I-II and pharmacokinetic study of imatinib mesylate in combination with irinotecan in patients with relapsed or refractory small-cell lung cancer, *Forum of clinical Oncology*, Vol 3, No 3 (2012).
44. A. Kalikaki, A. Koutsopoulos, M. Sfakianaki, E. Giannikaki, E. Kontopodis, S. Agelaki, J. Souglakos, A. Kotsakis, E. Lagoudaki, G. C. Georgiou, E. Tsakalaki, M. Trypaki, E. Papadimitraki, D. Mavroudis, V. Georgoulis, A. Voutsina. Detection of EGFR and KRAS mutations in NSCLC patients of Greek origin in daily clinical practice, *Forum of clinical Oncology*, Vol 4, No 3 (2013).

## **ΔΙΕΘΝΗΣ ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΤΥΠΟΣ**

### **Ι/ΠΛΗΡΗ ΑΡΘΡΑ**

1. V. Georgoulas, J.L. Misset, P. Ribaud, D. Machover, F.De Vassal, T. Droval, et al: Doxorubicin, Vincristine, Bleomycin, Cytembena and Cisplatin as combination chemotherapy for squamous cell lung cancer. *Anticancer Res* 3:107, 1983.
2. V. Georgoulas, A. Bourinbaiar, F. Amesland, C. Canon, H. Auclair, C. Jasmin: Colony formation in the absence of added growth factors by peripheral blood T-cell colony-forming cells of patients with T-cell malignancies. *Int J Cancer* 34:471, 1984.
3. V. Georgoulas, Y. Lunardi-Iskandar, F. Amesland, P. Ribaud, G. Mathe, C. Jasmin: In vitro sensitivity of myeloblast clonogenic cells to doxorubicin, aclacinomycin A and 4-0-Tetrapyramyl-Doxorubicin. *J Clin Oncol* 2:1215-1222,1984.
4. V. Georgoulas, M. Auclair, C. Jasmin: Heterogeneity of peripheral blood T-cell colony-forming cells in patients with T-cell malignancies. *Leuk Res* 8:1025, 1984.
5. V. Georgoulas, S. Marion, R. Consolini, C. Jasmin: Characterization of normal peripheral blood T and B cell colony-forming cells: Growth factor(s) and accessory cell requirements for their in vitro proliferation. *Cell Immunol* 90:1, 1985.
6. Y. Lunardi-Iskandar, V. Georgoulas, M. Allouche, W. Rozenbaum et al: Abnormal in vitro proliferation and differentiation of T colony-forming cells in AIDS patients and clinically normal male homosexuals. *Clin Exp Immunol* 10:285,1985.
7. V. Georgoulas and C. Jasmin: Accessory role of autologous T lymphocytes and adherent cells from patients with T-cell Acute Lymphoblastic Leukemia. *Leuk Res*9:357, 1985.
8. V. Georgoulas, Y. Lunardi-Iskandar, P. Ribaud, G. Mathe, C. Jasmin: Chemosensitivity of myeloblast clonogenic cells to Anthracyclins and correlation with clinical response. *Chemotherapia* 24:1186, 1985.
9. M. Allouche, A. Bourinbaiar, V. Georgoulas, R. Consoloni, A. Salvatore, H. Auclair and C. Jasmin: T-cell lineage involvement in lymphoid blast crisis of chronic myeloid leukemia. *Blood* 66:1155, 1985.
10. M. Allouche, P. Barreau, T. Comme et al: Third Workshop on Interleukin 2:Ed.Y.Jacques and J.P.Soulilou. *Lymphokine Res* 4:159, 1985.
11. V. Georgoulas, F. Triebel, C. Kosmatopoulos, M. Allouche, J.C. Gluckmann, G. Mathe, C. Jasmin: T-cell colony formation in patients with T cell malignancies:Growth factor requirements for in vitro proliferation of peripheral blood T cell colony-forming cells. *Leuk Res* 10:419, 1986.



12. C. Kosmatopoulos, M. Allouche, F. Triebel, M. Zanti, C. Clemenceau, J.C. Gluckmann, C. Jasmin, V. Georgoulas: Media conditioned by human leukemic T cells induce expression of IL2 receptors and proliferation of normal T lymphocytes. *Int J Cancer* 37:247, 1986.
13. Y. Lunardi-Iskandar, V. Georgoulas, W. Rozenbaum, D. Klatzmann, M. Cavaille-Coll, P. Meyer, M. Gentilini, J.C. Gluckmann, C.J. Jasmin: Abnormal in vitro proliferation and differentiation of T colony-forming cells in patients with lymphadenopathy syndrome (LAS). *Blood* 67:1063, 1986.
14. R. Consolini, J. Breard, A. Bourinbaiar, A. Goutner, V. Georgoulas, C. Canon, E. Brugerie, G. Mathe: Abnormal in vitro differentiation of peripheral blood clonogenic B cells in common acute lymphoblastic leukemia during complete remission. *Blood* 67:796, 1986.
15. Y. Lunardi-Iskandar, V. Georgoulas, et al: AIDS and LAS patients display similar abnormal in vitro proliferation and differentiation of T colony forming cells (T-CFC). *Cancer Detect Prev* 1:525, 1987.
16. M. Bentaboulet, M. Allouche, A. Tsapis, C. Jasmin, V. Georgoulas: Characterization of interleukin-2 receptors expressed on acute leukemic B-cells. *Blood* 70: 954-959, 1987.
17. J. Laborda, J. Naval, M. Allouche, M. Calvo, V. Georgoulas, Z. Mishal, J. Uriel: Specific uptake of alpha-fetoprotein by malignant human lymphoid cells. *Int J Cancer* 40: 314, 1987.
18. Y. Lunardi-Iskandar, V. Georgoulas, D. Vittecoq, M.T. Nygeyre et al: Peripheral blood adherent cells from AIDS patients inhibit normal T colony growth through decreased expression of Interleukin 2-receptors and production of Interleukin 2. *Leuk Res* 11:753, 1987.
19. M. Allouche, V. Georgoulas, A. Bourinbaiar, I. Dupuy et al: Abnormal proliferation of T colony-forming cells from peripheral blood of patients with T-cell acute lymphoblastic leukemias and lymphomas in complete remission: Potential prognostic value. *Brit J Haematol* 65:411, 1987.
20. V. Georgoulas, M. Allouche, A. Salvatore, C. Clemenceau, C. Jasmin: Interleukin 2 responsiveness of immature T-cell colony-forming cells (T-CFC) from patients with acute T-cell lymphoblastic leukemia. *Cell Immunol* 105:317, 1987.
21. Y. Lunardi-Iskandar, V. Georgoulas, D. Vittecoq, A. Ammar et al: Prognostic value of blood and bone marrow T colony-forming cells (T.CFC) in patients with lymphadenopathy syndrome (LAS). *Biomed Pharmacother* 42:21, 1988.

22. Lunardi-Iskandar, M.T. Nugyere, V. Georgoulis, F. Barre-Sinoussi, C. Jasmin, J.C. Chermann: Replication of the human immunodeficiency virus-1 and impaired differentiation of T cells following in vitro infection of bone marrow immature T cells. *J Clin Invest* 83:610, 1989.
23. Y. Lunardi-Iskandar, V. Georgoulis, AM. Bertoli, Y. Augery-Bourget, A. Ammar, D. Vittecoq, W. Rozenbaum, P. Meyer, C. Jasmin: Impaired in vitro proliferation of hemopoietic precursors in HIV-1 infected subjects. *Leuk Res* 13:573-581, 1989.
24. M. Allouche, Y. Sahraoui, Y. Augery-Bourget, Y. Ohashi, K. Sygamura, C. Jasmin, V. Georgoulis: Presence of a p70 IL2-binding peptide on leukemic cells from various hematopoietic lineages. *J Immunol* 143:2223, 1989.
25. M. Allouche, V. Georgoulis, Y. Augery-Bourget, Y. Sahraoui, A. Tsapis, M. Perraki, C. Clemanceau, V. Choulakis, C. Jasmin: Phorbol Myristate Acetate induces both high affinity and low affinity interleukin 2-receptors on a pre-B leukemic cell line. *Leuk Res* 14:353, 1990.
26. M. Allouche, Y. Lunardi-Iskandar, C. Varella-Millot, M. Itzaki, P. Cornuet, C. Jasmin, V. Georgoulis: Effect of Phorbol Myristate Acetate on T cell colony-formation, IL2-receptor expression and IL2-production by cells from patients at all stages of HIV-infection. *Clin Exp Immunol* 81:200, 1990.
27. C. Stournaras, E. Spanakis, M. Perraki, M. Athanasiou, D. Thanos, V. Georgoulis: Triethyllead-induced inhibition of normal human lymphocytes through decreased expression of the Tac chain of Interleukin 2 receptor. *Intern J Immunother* 12:379-358, 1990.
28. J. Uriel, Y. Lunardi-Iskandar, J. Laborda, J.M. Torres, J. Naval, V. Georgoulis, R. Lowi, C. Jasmin, Mishal M.: Defective uptake of Alpha-Fetoprotein (AFP) and Transferrin (TF) by PHA-activated peripheral blood lymphocytes from patients with AIDS and related syndromes: *AIDS Res Human Retrov* 16: 401, 1990.
29. V. Georgoulis, A. Agelakis, P. Fountouli, A. Darivianakis, K. Bibakis, E. Nikoloudis, A. Ammar, AM. Bertoli, Malliaraki-Pinetidou Seroprevalence of HIV-2 infection in Greece (Crete). *J AIDS* 3:1188, 1990.
30. M. Allouche, Y.Sahraoui, Y. Augery-Bourget, M. Perraki, C. Jasmin, V. Georgoulis: Interleukin 2 receptors. *Leuk Res* 14:690, 1990.
31. C. Jasmin, M. Allouche, C. Le Bousse-Kerlides, F. Smadja-Joffe, P. Krief, V. Georgoulis, C. Boucheix.: The role of growth factor receptor (excluding IL-2 receptors) in the

- proliferation and differentiation of normal and leukemic hematopoietic cells. *Leuk Res* 14:695, 1990.
32. C. Jasmin, V. Georgoulis, F. Smadja-Joffe, C. Boucheix, C. Le Bousse-Kerlides, M. Allouche, C. Cibert, B. Azzarone: Autocrine growth of leukemic cells. *Leuk Res* 14:689, 1990.
  33. D. Thanos, M. Allouche, Y. Sahraoui, E. Spanakis, M. Perraki, E. Papadogiorkaki, V. Galanopoulos, J. Papamatheakis, C. Jasmin, V. Georgoulis: Intracytoplasmic detection of the Tac (p55) chain of Interleukin 2 receptor in pre-B leukemic cells followed by a constitutive expression of Tac mRNA. *Leukemia* 4:819, 1990.
  34. A. Ammar, C. Cibert, A.M. Bertoli, V. Tsilivakos, C. Jasmin, V. Georgoulis: Biological and biochemical characterization of a factor produced spontaneously by adherent cells of HIV-infected patients inhibiting Tac expression on normal T cells. *J Clin Invest* 87: 2048, 1991.
  35. A. Ammar, A.M. Bertoli, V. Sahraoui, V. Tsilivakos, M. Perraki, P. Meyer, W. Rosenbaum, C. Jasmin, V. Georgoulis.: Production of a monocyte-derived Tac inhibitory factor from subjects at all clinical stages of HIV infection. *J AIDS* 4:1208, 1991.
  36. Antonakis, E. Marcogianakis, M. Theodoropoulou, V. Georgoulis, C. Stournaras, A. Gravanis: The antiglucocorticoid RU486 down regulates the expression of Interleukin 2 receptors in normal human lymphocytes. *J Ster Bioch Mol Biol* 39: 929, 1991.
  37. N. Antonakis, V. Georgoulis, C. Stournaras, A. Gravanis: Effects of glycocorticoids on the expression of Interleukin 2 receptor in human lymphocytes. *Bioch Biophysics* 32:23, 1991.
  38. A. Symeonidis, A. Kouraki, P. Katevas, M. Perraki, M. Tiniakou, P. Matsouka, V. Georgoulis, N. Zoumbos: Immune fuction parameters at diagnosis in patients with myelodysplatic syndroms: correlation with the FAB classification and prognosis. *Eur J Haematol* 47: 277, 1991.
  39. C. Stournaras, J. Saridakis, Y. Fostinis, V. Georgoulis: Interaction of Captan with mammalian microtubules. *Cell Bioch Function* 9:23, 1991.
  40. Y. Sahraoui, A. Ammar, A.M. Bertoli, C. Clemenceau, N. N'Go, A. Tsapis, E. Spanakis, M. Allouche, C. Jasmin, V. Georgoulis: Abnormal expression of IL-2R $\beta$  (p70) subunit on HIV-infected patients cells. *Cell Immunol* 139:318, 1992.
  41. A. Ammar, Y. Sahraoui, A. Tsapis, A.M. Bertoli, C. Jasmin, V. Georgoulis: Human Immunodeficiency Virus-infected adherent cell-derived inhibitory factor (p29) inhibits

- normal T cell proliferation through decreased expression of high affinity Interleukin 2 receptors and production of Interleukin 2. *J Clin Invest* 90:8, 1992.
42. Y. Sahraoui, M. Allouche, A. Ammar, E. Spanakis, C. Clemenceau, C. Jasmin, M. Perraki, C. Varella-Millot, V. Georgoulis: Interleukin 2 production and Interleukin 2 receptor expression by human immature leukemic T cells. *Leukemia* 6:1025, 1992.
  43. Y. Sahraoui, M. Allouche, M. Perraki, C. Clemenceau, C. Jasmin, V. Georgoulis: Phorbol Myristate Acetate-induced expression of high-affinity Interleukin 2 receptors and production of Interleukin 2 by human acute lymphoblastic leukemia T cells. *Leukemia* 6:295, 1992.
  44. M. Kalmanti, H. Karamolegou, H. Dimitriou, A. Toska, J. Vlachonicolis, M. Perraki, V. Georgoulis, T. Kalmanti: Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. *Int J Hematol.* 57:147, 1993.
  45. A. Ammar, A.M. Bertoli, S. Chouaib, C. Clemenceau, C. Jasmin, V. Georgoulis: IL-2Ra chain inhibitory factor (p29) produced by HIV-infected macrophages: Cell target and mode of action. *Cell Immunol* 152:358, 1993.
  46. A. Psychoyos, G. Creatsas, E. Hassan, V. Georgoulis, A. Gravanis: Spermicidal and antiviral properties of cholic acid: Contraceptive efficacy of a new vaginal sponge (Protectaid) containing sodium cholate. *Human Reprod* 8:866, 1993.
  47. E. Drakopoulou, G. Sotiropoulou, V. Tsilivakos, V. Georgoulis, P. Cordopatis: Synthetic peptides from the region 30-54 of the Interleukin-2 receptor  $\beta$ -chain (IL-2R $\beta$ ) affect IL-2 binding to human T-cells. *Collect Czech Chem Commun* 59:943-949, 1994.
  48. V. Tsilivakos, A. Tsapis, S. Kakolyris, P. Iliakis, M. Perraki, V. Georgoulis: Characterization of Interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. *Leukemia* 8:1571, 1994.
  49. N. Antonakis, V. Georgoulis, A. Margioris, C. Stournaras, A. Gravanis: In vitro differential effects of the antigluocorticoid RU486 on the release of lymphokines from mitogen-activated normal human lymphocytes. *J Steroid Bioch Molec Biol* 51:67, 1994.
  50. E. Koumantakis, I. Matalliotakis, M. Neonaki, G. Froudarakis, V. Georgoulis: Soluble serum interleukin-2 receptor, interleukin 6, and interleukin 1 $\alpha$  in patients with endometriosis and in controls. *Arch Gynecol Obstet* 255:107, 1994.

51. E. Koumantakis, I. Matalliotakis, A. Makrigiannakis, M. Neonaki, V. Georgoulas: Danazol suppress both cell-mediated and humoral immune responses. *Adv Contracept Deliv Systems* 10:267, 1994.
52. J. Apostolakis, M. Toumbis, K. Kostantopoulos, D. Kamaroulias, J. Anagnostakis, V. Georgoulas, Ph. Fessas, J. Zervas: HLA antigens and asthma in Greeks. *Resp Med* 90: 201, 1996.
53. E. Hassan, G. Creatsas, A. Gravanis, V. Georgoulas, A. Psychoyos: Anti-STDs vaginal contraceptive sponges. *Ann NY Acad Sci* 816(17): 451-456, 1997.
54. V. Georgoulas, N. Malliaraki, M. Theodoropoulou, E. Spanakis, P. Fountouli, D. Tsatsaki, S. Kotsaki, A. Karvela-Agelaki, E. Malliaraki, Pinetidou: Indeterminate human immunodeficiency virus type 1 Western Blot may indicate an abortive infection in some low-risk blood donors. *Transfusion* 37: 65, 1997.
55. Y. Sahraoui, M. Perraki, M. Theodoropoulou, M. Allouche, A. Tsapis, A. Ammar, C. Clemenceau, S. Bokogiorgou, T. Yacici, G. Katrinakis, C. Jasmin, V. Georgoulas: Autocrine IL-2-dependent growth of a newly established CD3<sup>-</sup>, CD16<sup>-</sup>, CD56<sup>+</sup>, CD57<sup>+</sup>, JH<sup>-</sup>, TCR<sub>B</sub><sup>-</sup>, TCR<sub>γ</sub><sup>-</sup> leukemia cell line (NOI-90). *Leukemia* 11: 245, 1997.
56. G. Samonis, D. Bafaloukos, AN. Margioris, G. Katsarma, P. Toloudis, C. Bacoyannis, N. Karvounis, V. Georgoulas, P. Kosmidis: First-line chemotherapy of advanced breast cancer with a combination of Mitoxantrone, Methotrexate and Vincristine (MIMO). *Oncology* 54:371, 1997.
57. D.P. Mikhailidis, E. S. Ganotakis, V. A. Georgoulas, D. T. Vallance, A. F. Winder: Tamoxifen-induced hypertriglyceridaemia: seven cases reports and suggestions for remedial action. *Oncol Rep* 4: 625-628, 1997.
58. E. Giannikaki, Ch. Kouvidou, M. Tzardi, K. Stefanaki, K. Koutsoubi, M. Gregoriou, E. Zois, S. Kakolyris, C. Mavroudi, G. Delides, V. Georgoulas, P. Kanavaros: p53 protein expression in breast carcinomas: comparative study with the wild type p53-induced proteins mdm<sup>2</sup> and p21/waf. *Anticancer Res* 17:2123, 1997.
59. K. E. Valassiadou, K. Stefanaki, M. Tzardi, G. Datsaris, V. Georgoulas, J. Melissas, D. Tsiftsis, G. Delides, P. Kanavaros: Immunochemical expression of p53, bcl-2, mdm2 and waf/21 proteins in colorectal adenocarcinomas. *Anticancer Res* 17:2571, 1997.
60. Ch. Kouvidou, K. Stefanaki, Y. Dai, M. Tzardi, K. Koutsoubi, K. Darivianaki, E. Karidi, D. Rondoyanni, E. Zois, S. Kakolyris, V. Georgoulas, G. Delides, P. Kanavaros: p21/waf1

- protein expression in nasopharyngeal carcinomas: Comparative study with PCNA, p53 and mdm2 protein expression. *Anticancer Res* 17: 2615, 1997.
61. M. I. Koukourakis, S. Koukouraki, A. Giatromanolaki, J. Skarlatos, V. Georgoulas, N. Karkavitsas: Non-small cell lung cancer functional imaging: increased Hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment. *Clin Cancer Res* 3: 749, 1997.
  62. E. Markogiannakis, V. Georgoulas, A. N. Margioris, E. Zoumakis, Ch. Stournaras, A. Gravanis: Estrogens and glucocorticosteroids induce the expression of c-erbB2/neu receptor in the Ishikawa human endometrial cells. *Life Science* 61:1083, 1997.
  63. V. Georgoulas, Ch. Kouroussis, S. Kakolyris, N. Androulakis, MA. Dimopoulos, E. Papadakis, Th. Kotsakis, N. Vardakis, K. Kalbakis, N. Merambeliotakis, D. Hatzidaki: Second-line treatment of advanced non-small cell lung cancer with Paclitaxel and Gemcitabine: A preliminary report on an active regimen. *Semin Oncol* 24(suppl 12): 61, 1997.
  64. V. Georgoulas, Ch. Kouroussis, N. Androulakis, S. Kakolyris, M-A. Dimopoulos, Ch. Papadimitriou, K. Hatzakis, P. Heras, K. Kalbakis, Th. Kotsakis, N. Vardakis, N. Merambeliotakis, D. Hatzidaki: Docetaxel (Taxotere) and Gemcitabine (Gemsar) in the treatment of non-small cell lung cancer (NSCLC): Preliminary results. *Semin Oncol* 24 (suppl 14): 22-25, 1997.
  65. V. Georgoulas, Ch. Kouroussis, N. Androulakis, S. Kakolyris, E. Papadakis, D. Bouros, F. Apostolopoulou, Th. Georgopoulou, M. Agelidou, D. Bouros, J. Souglakos, G. Halkiadakis, D. Hatzidaki: Docetaxel (Taxotere) and Vinorelbine (Navelbine) in the treatment of non-small cell lung cancer (NSCLC). *Semin Oncol* 24 (suppl 14): 9-14, 1997.
  66. J. Mataliotakis, M. Neonaki, A. Zolindaki, E. Hassan, V. Georgoulas, E. Koumantakis: Changes in immunological variables (TNF- $\alpha$ , SD8, SCD4) during danazol treatment in patients with endometriosis. *Int J Fertil Women Med* 42: 211, 1997.
  67. K. Vallasiadou, K. Stefanaki, I. Vlachonikolis, E. Sanidas, D. Tsiftsis, I. Melissas, V. Georgoulas, S. Kakolyris, G. Delides, P. Kanavaros: Immunohistochemical expression of MIB1 (KI-67) protein in colorectal adenocarcinomas. *Eur J Pathol* 17: 2571, 1997.
  68. S. Kakolyris, N. Androulakis, Ch. Kouroussis, A. Kotsakis, J. Souglakos, D. Hatzidaki, D. Beri, G. Samonis, V. Georgoulas: Vinorelbine and tamoxifen as first-and second-line treatment in elderly patients with advanced breast cancer: A preliminary analysis. *J BUON* 3: 219-226, 1997.

69. J. Vlachonikolis, V. Georgoulas: Mortality from malignant neoplasms in Crete, 1992-1993. *J Epidem Commun Health* 52(2): 126-127, 1998.
70. M.I. Koukourakis, C. Kouroussis, M. Kamilakis, S. Koukouraki, A. Giatromanolaki, S. Kakolyris, A. Kotsakis, N. Androulakis, N. Bachlitzanakis, V. Georgoulas: Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer: A phase I/II dose escalation trial. *Eur J Cancer* 34 (6): 838-844, 1998.
71. K. Stefanaki, D. Rontoyiannis, C. Vamvouka, S. Bolioti, V. Chaniotis, F. Sotsiou, M. Vlychou, G. Delidis, S. Kakolyris, V. Georgoulas, P. Kanavaros: Immunohistochemical detection of bcl-2, p53, mdm-2 and p21/waf proteins in small-cell lung carcinomas. *Anticancer Res* 18: 1689-1696, 1998.
72. K. Stefanaki, D. Rontoyiannis, C. Vamvouka, S. Bolioti, V. Chaniotis, F. Sotsiou, M. Vlychou, G. Delidis, S. Kakolyris, V. Georgoulas, P. Kanavaros: Immunohistochemical detection of bcl-2, p53, mdm-2 and p21/waf proteins in small-cell lung carcinomas. *Anticancer Res* 18: 1167-1174, 1998.
73. Ch. Kouroussis, S. Kakolyris, N. Androulakis, P. Heras, J. Vlachonikolis, L. Vamvakas, M. Vlata, D. Hatzidaki, G. Samonis, V. Georgoulas: Salvage chemotherapy with paclitaxel, vinorelbine and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. *Am J Clin Oncol* 21 (3): 226-232, 1998.
74. V. Georgoulas, N. Androulakis, AM. Dimopoulos, Ch. Kouroussis, S. Kakolyris, E. Papadakis, F. Apostolopoulou, Ch. Papadimitriou, A. Vossos, M. Agelidou, P. Heras, S. Tzannes, J. Vlachonikolis, E. Mavromanolakis, D. Hatzidaki: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study. *Ann Oncol* 9: 331-334, 1998.
75. Ch. Kouroussis, N. Androulakis, S. Kakolyris, P. Heras, J. Souglakos, G. Metaxaris, G. Maltezas, G. Halkiadakis, D. Hatzidaki, J. Vlachonikolis, V. Georgoulas: First-line treatment of advanced non-small cell lung cancer with docetaxel and vinorelbine. *Cancer* 83: 2083-2090, 1998.
76. S. Kakolyris, G. Samonis, M. Koukourakis, J. Vlachonikolis, G. Chalkiadakis, K. Kalbakis, J. Souglakos, S. Agelaki, P. Toloudis, V. Georgoulas: Treatment of non-small cell lung cancer with prolonged oral etoposide (VP-16). *Am J Clin Oncol* 21 (5): 505-508, 1998.

77. M. Koukourakis, I. Stefanaki, A. Armanaki, Ch. Fragiadaki, V. Georgoulas, E. Koumandakis, A. Kranidis, E. Helidonis: Fractionated carboplatin radiosensitization: A phase I dose escalation study. *Am J Clin Oncol* 21 (6): 595-601, 1998.
78. G. Samonis, P. Skordilis, A. Maraki, G. Datsaris, P. Toloudis, I. Chatzinikolaou, V. Georgoulas, GP. Bodey: Oropharyngeal candidiasis as marker for esophageal candidiasis in cancer patients. *J Inf Dis* 27: 283-286, 1998.
79. V. Georgoulas, N. Androulakis, D. Bouros, Ch. Kouroussis, K. Chatzakis, E. Papadakis, F. Apostolopoulou, Th. Georgopoulou, A. Kotsakis, J. Souglakos, D. Hatzidaki, J. Vlachonikolis, G. Panagos: Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small cell lung cancer: A multicenter phase II study of the Greek Cooperative Group for Lung Cancer. *Lung Cancer* 21: 213-220, 1998.
80. S. Kakolyris, L. Kaklamanis, A. Giatromanolaki, M. Koukourakis, V. Georgoulas, KC. Gatter, AL. Harris: Expression and subcellular localization of human AP endonuclease 1 (HAP 1) protein in normal tissues. *Histopathology* 33: 561-569, 1998.
81. K. Stefanaki, M. Tzardi, Ch. Kouvidou, V. Chaniotis, M. Bolioti, M. Vlychou, M. Zois, S. Kakolyris, G. Delidis, D. Rontoyianni, P. Kanavaros, V. Georgoulas: Expression of p53, p21 mdm2, Rb, bax and Ki67 proteins in lymphomas of the Mucosa Associated Lymphoid (MALT) Tissue. *Anticancer Res* 18: 2403-2408, 1998.
82. N. Androulakis, Ch. Kouroussis, S. Kakolyris, S. Tzannes, E. Papadakis, Ch. Papadimitriou, A. Geroyianni, Th. Georgopoulou., I. Dimopoulou, J. Souglakos, A. Kotsakis, N. Vardakis, D. Hadzidaki, V. Georgoulas: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin-or-docetaxel-based chemotherapy: A multicenter phase II study. *Ann Oncol* 9: 1127-1130, 1998.
83. K. Alexopoulos, Ch. Kouroussis, N. Androulakis, E. Papadakis, M. Valsamatzis, S. Kakolyris, G. Samelis, E. Patila, A. Vossos, E. Samantas, V. Georgoulas: Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial. *Cancer Chemoth Pharmacol* 43: 257-262, 1999.
84. A. Giatromanolaki, M. Koukourakis, Th. Zamboukas, A. Skordalaki, P. Arapandoni, V. Georgoulas, G. Fountzilias: P53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum-based chemotherapy and radiotherapy. *Anticancer Res* 18: 4685-4692, 1998.



85. A. Giatromanolaki, G. Foutzilias, M. Koukourakis, P. Arapandoni, V. Theologi, S. Kakolyris, V. Georgoulis, A. Harris, KC. Gatter: Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. *Clin Exper Metast* 16: 665-672, 1998.
86. I.G. Vlachonicolis, M. Mavromanolakis, V. Georgoulis: Descriptive epidemiology of cancer in Crete, Greece, 1994: I. Gynaecological cancers. *J BUON* 3: 245-250, 1998.
87. G. Aravandinos, D. Skarlos, P. Kosmidis, V. Georgoulis, I. Sgouros, D. Bafaloukos, N. Androulakis, S. Florou, A. Athanasiades, G. Fountzilias: Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5FU based chemotherapy. *Crit Rev Oncol Hemat* 32(3): 209-219, 1999.
88. D. Mavroudis, N. Malamos, A. Alexopoulos, Ch. Kouroussis, S. Agelaki, E. Sarra, A. Potamianou, Ch. Kosmas, G. Rigatos, Th. Giannakakis, K. Kalbakis, F. Apostolaki, J. Vlachonikolis, S. Kakolyris, G. Samonis, V. Georgoulis: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. *Ann Oncol* 10(2): 211-215, 1999.
89. Ch. Kouroussis, N. Androulakis, S. Kakolyris, J. Souglakos, A. Kotsakis, D. Mavroudis, K. Katsogridakis, N. Vardakis, D. Hatzidaki, G. Samonis, J. Vlachonikolis, V. Georgoulis: Dose-escalation study of docetaxel in combination with mitoxantrone as first line treatment in patients with metastatic breast cancer. *J Clin Oncol* 17 (3): 862-869, 1999.
90. V. Georgoulis, Ch. Kouroussis, N. Androulakis, S. Kakolyris, AM. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, Ch. Papadimitriou, A. Agelidou, K. Hatzakis, K. Kalbakis, A. Kotsakis, N. Vardakis, J. Vlachonikolis: Front line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. *J Clin Oncol* 17 (3): 914-920, 1999.
91. P. Kanavaros, K. Stefanaki, K. Valassiadou, J. Vlachonikolis, M. Mavromanolakis, M. Vlychou, S. Kakolyris, V. Gorgoulis, M. Tzardi, V. Georgoulis: Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas. *Med Oncol* 16: 23-30, 1999.
92. E. Sarra, A. Kotsakis, J. Souglakos, Ch. Kouroussis, S. Kakolyris, E. Mavromanolakis, J. Vlachonikolis, V. Georgoulis: Post-chemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4<sup>+</sup> cell proliferation. *Anticancer Res* 19: 471-476, 1999.

93. A. Giatromanolaki, M. Koukourakis, V. Georgoulas, K.C. Gatter, A.L. Harris, G. Fountzilias: Angiogenesis vs response after combined chemotherapy of squamous cell head and neck cancer. *Int J Cancer* 80: 810-817, 1999.
94. S. Kakolyris, G. Samonis, M. Koukourakis, G. Vlachonikolis, K. Kalbakis, S. Agelaki, G. Chalkiadakis, E. Sanidas, D. Tsiftsis, V. Georgoulas: First-line treatment with Mitoxantrone, Methotrexate, Vincristine, and Carboplatine (MIMOC) plus cyclical hormonotherapy with Tamoxifen and Megestrol Acetate in advanced breast cancer. *Am J Clin Oncol* 22: 273-277, 1999.
95. M. Koukourakis, A. Giatromanolaki, S. Kakolyris, H. Kastanas, S. Shiza, A. Kranidis, E. Koumantakis, N. Bahlitzanakis, V. Georgoulas: Concurrent twice-a-week docetaxel and radiotherapy. A phase I dose escalation trial with immunological toxicity evaluation. In: *J Rad Oncol Biol* 43(1): 107-114, 1999.
96. A. Giatromanolaki, M. Koukourakis, S. Kakolyris, H. Turley, K. O'Byrne, P. Scott, F. Pezella, V. Georgoulas, K.C. Gatter, A.L. Harris: Vascular endothelial growth factor, p53 and angiogenesis in lung cancer. *Clin Cancer Res* 4 (12): 3017-3024, 1999.
97. S. Kakolyris, A. Giatromanolaki, M. Koukourakis, L. Kaklamanis, P. Kanavaros, I. Hickson, V. Georgoulas, K.C. Gatter, A.L. Harris: Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) correlates with prognosis in early operable non small cell lung cancer (NSCLC): *J Pathol* 189: 351-357, 1999.
98. Ch. Kouroussis, E. Xydakis, A. Potamianou, Th. Giannakakis, S. Kakolyris, S. Agelaki, E. Sarra, N. Malamos, A. Alexopoulos, D. Mavroudis, G. Samonis, S. Papadouris, V. Georgoulas, G. Panagos: For the Greek Breast Cancer Cooperative Group (GBCCG): Front-line treatment of metastatic breast cancer with docetaxel and epirubicin. A multicenter dose-escalation study. *Ann Oncol* 10: 547-552, 1999.
99. J. Vlachonikolis, M. Mavromanolakis, V. Georgoulas: Descriptive epidemiology of cancer in Crete, Greece, 1994: Part II; Gastrointestinal cancers. *J. BUON* 4: 73-81, 1999.
100. N. Androulakis, Ch. Kouroussis, S. Kakolyris, AM Dimopoulos, G. Samelis, N. Tsavaris, K. Genetas, G. Panagos, G. Aravandinos, Ch. Papadimitriou, S. Karabekios, G. Stathopoulos, V. Georgoulas: Treatment of pancreatic cancer with docetaxel and granulocyte-colony stimulating factor: A multicenter phase II study. *J Clin Oncol* 17 (6): 1779-1785, 1999.
101. S. Kakolyris, Ch. Kouroussis, M. Koukourakis, N. Androulakis, L. Vamvakas, S. Agelaki, D. Hatzidaki, G. Samonis, D. Tsiftis, V. Georgoulas: First line treatment of metastatic

- breast cancer with mitoxantrone, vinorelbine, and carboplatin. *Am J Clin Oncol* 22(6): 568-572, 1999.
- 102.** M. Koukourakis, N. Bahlitzanakis, M. Froudarakis, A. Giatromanolaki, V. Georgoulis, S. Koumiotaki, M. Christodoulou, G. Kyrias, J. Skarlatos, J. Konstantelos, K. Beroukas: Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small cell lung cancer. *Br J Cancer* 80(11): 1792-1796, 1999.
- 103.** P. Theodoropoulos, H. Polioudaki, O. Kotsaki, S. Derds, V. Georgoulis, C. Dargemont, S. Georgatos: Taxol affects nuclear lamina and pore complex organization and inhibits import of karyophilic proteins into the cell nucleus. *Cancer Res* 59(Sept15): 4625-4633, 1999.
- 104.** S. Kakolyris, Giatromanolaki A., Koukourakis M., Leigh I., Georgoulis V., Kanavaros P., Sivridis E., Gatter K., Harris A: Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39. Correlation with p53 and angiogenic factor expression. *Cancer Res* 59(Nov 1): 5602-5607, 1999.
- 105.** A. Giatromanolaki, E. Sivridis, M. Koukourakis, V. Georgoulis, K. Gatter, A. Harris: Intratumoral angiogenesis: A new prognostic indicator for stage I endometrial adenocarcinomas? *Oncology Res* 11(4): 205-212, 1999.
- 106.** A. Giatromanolaki, G. Stathopoulos, E. Tsiobanou, C. Papadimitriou, V. Georgoulis, K. Gatter, A. Harris, M. Koukourakis: Combined role of tumor angiogenesis, bcl-2 and p53 expression in the prognosis of colorectal carcinoma. *Cancer* 86(8): 1421-1430, 1999.
- 107.** P. Kanavaros, K. Stefanaki, D. Rontogianni, K. Darivianaki, M. Vlychou, E. Papadaki, G. Eliopoulos, M. Bakiri, C. Matsouka, S. Kakolyris, V. Georgoulis: Immunohistochemical detection of p53, mdm2, waf1/p21 and Ki67 proteins in bone marrow biopsies in myelodysplastic syndromes, acute myelogenous leukaemias and chronic myeloproliferative disorders. *Clin Exp Path* 47(5): 231-238, 1999.
- 108.** Ch. Kouroussis, V. Georgoulis, E. Simvoulakis, S. Karabekios, G. Samonis: Spontaneous Spondylodiscitis caused by *Klebsiella pneumoniae*. *Infection* 6: 368-369, 1999.
- 109.** M.A. Dimopoulos, C. Bakoyannis, V. Georgoulis, C. Papadimitriou, L.A. Mouloupoulos, C. Deliveliotis, A. Karayannis, I.Varkarakis, G. Aravantinos, A. Zervas, D. Pantazopoulos, G. Fountzilias, A. Baniasis, Z. Kyriakakis, A. Anagnostopoulos, A. Giannopoulos, P. Kosmidis: Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. *Ann Oncol* 10: 1385-1388, 1999.

110. P. Kanavaros, M. Vlychou, S. Stefanaki, D. Rontoyianni, P. Gaulard, E. Pantelidaki, M. Zois, K. Darivianaki, V. Georgoulis, ML. Bouland, V. Georgoulis, C. Kittas: Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease. *Anticancer Res* 19(2A): 1209-1216, 1999.
111. S. Kakolyris and V. Georgoulis: The role of gemcitabine and paclitaxel as second-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). *Clin Lung Cancer* 2 (1): 43-47, 2000.
112. D. Mavroudis, Ch. Kouroussis, N. Androulakis, K. Kalbakis, S. Agelaki, S. Kakolyris, J. Souglakos, E. Sarra, N. Vardakis, D. Hatzidaki, G. Samonis, V. Georgoulis: Front-line treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial. *Am J Clin Oncol* 23(4): 341-344, 2000.
113. M. Koukourakis, A. Giatromanolaki, S. Kakolyris, M. Froudarakis, V. Georgoulis, G. Retalis, N. Bahlitzanakis: Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. *Med Oncol* 17: 135-143, 2000.
114. M. Koukourakis, A. Giatromanolaki, F. Guddo, L. Kaklamanakis, M. Vignola, S. Kakolyris, H. Turley, V. Georgoulis, G. Bonsignore, K.C. Gatter, A.L. Harris: c-erbB-2 and episialin challenge host immune response by HLA-class I expression in human non-small cell lung cancer. *J. Immunoth.*23: 104-114, 2000.
115. P. Kanavaros, K. Stefanaki, J. Vlachonikolis, G. Eliopoulos, S. Kakolyris, D. Rontogianni, V. Gorgoulis, V. Georgoulis: Expression of p53/waf1, bcl-2, Rb and Ki67 proteins in Hodgkin's lymphomas. *Histol Histopathol* 15: 445-453, 2000.
116. A. Kotsakis, E. Sarra, M. Peraki, M. Koukourakis, S. Apostolaki, J. Souglakos, E. Mavromanolakis, J. Vlachonikolis, V. Georgoulis: Docetaxel-induced lymphopenia in patients with solid tumors: A prospective phenotypic analysis. *Cancer* 15(89): 1380-1386, 2000.
117. S. Kakolyris, J. Souglakos, S. Agelaki, Ch. Kouroussis, D. Mavroudis, E. Sarra, P. Malliotakis, V. Georgoulis: A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy. *Lung Cancer* 30 (3): 193-198, 2000.

118. S. Kakolyris, Ch. Kouroussis, K. Kalbakis, D. Mavroudis, J. Souglakos, N. Vardakis, S. Kremos, V. Georgoulas: Salvage treatment of advanced non-small cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin. *Ann Oncol* 11: 757-760, 2000.
119. E. Chatzaki, A.N. Margioris, A. Makrigiannakis, E. Castanas, V. Georgoulas, A. Gravanis: Kappa opioids and transforming growth factor beta 1 interact in human endometrial cells. *Hum Reprod, Mol Hum Reprod* 6(7): 602-609, 2000.
120. S. Kakolyris, L. Kaklamanis, M. Koukourakis, A. Giatromanolaki, A. Rousomoustakaki, J. Souglakos, D. Reppa, V. Georgoulas, K. Gatter, A. Harris: Angiogenesis and p53 expression in the colorectal adenoma-carcinoma sequence. *Oncol Res* 12(4): 203-208, 2000.
121. M. Koukourakis, A. Giatromanolaki, P. Thorpe, RA. Brekken, E. Sivridis, S. Kakolyris, V. Georgoulas, KC. Gatter, AL. Harris: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. *Cancer Res* 60(11): 3088-3095, 2000.
122. Ch. Kouroussis, G. Samonis, N. Androulakis, J. Souglakos, A. Voloudaki, A.M. Dimopoulos, A. Kotsakis, S. Kakolyris, K. Kalbakis, V. Georgoulas: Successful conservative treatment of neutropenic enterocolitis complicating taxane based chemotherapy: a report of five cases. *Am J Clin Oncol* 23(3): 309-313, 2000.
123. M. Koukourakis, S. Koukouraki, A. Giatromanolaki, S. Kakolyris, V. Georgoulas, A. Velidaki, S. Archimandritis, N. Karkavitsas: High intratumoral accumulation of stealth liposomal doxorubicin (Caelyx) in locally advanced sarcomas provides strong rationale for combination with radiotherapy. *Acta Oncol* 39(2): 207-211, 2000.
124. D. Mavroudis, Ch. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, G. Samonis, V. Georgoulas: Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report. *Semin Oncol* 27(1): 25-30, 2000.
125. T. Giannakakis, N. Ziras, S. Kakolyris, D. Mavroudis, N. Androulakis, S. Agelaki, M. Parashos, E. Sarra, Th. Dimou, D. Hatzidaki, J. Vlachonikolis, V. Georgoulas: Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung cancer: A multicenter phase I study. *Eur J Cancer* 36: 742-747, 2000.
126. M. Koukourakis, G. Kyrias, S. Kakolyris, Ch. Kouroussis, C. Fragiadaki, E. Geradaki, A. Giatromanolaki, V. Georgoulas, G. Retalis: Subcutaneous amifostine during fractionated

- radiotherapy for lung, pelvic and head and neck cancer: A randomized phase II study. *J Clin Oncol* 18(11): 2226-2233, 2000.
127. E. Papadakis, S. Agelaki, E. Banis, A. Agelidou, A. Harpidou, K. Kalbakis, A. Rapti, M. Agelidou, X. Tsiadaki, E. Sarra, J. Souglakos, Ph. Palamidis, N. Vardakis, V. Georgoulas: Salvage treatment with vinorelbine and ifosfamide in patients with non-small cell lung cancer: A multicenter phase II study. *J BUON*, 5: 135-140, 2000.
  128. A. Giatromanolaki, M. Koukourakis, GP. Stathopoulos, A. Kapsoritakis, G. Paspatis, S. Kakolyris, E. Sivridis, V. Georgoulas, AL. Harris, KC. Gatter: Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase and of p53 protein expression in locally advanced gastric cancer. *Oncol Res* 12: 33-41, 2000.
  129. Ch. Kouroussis, S. Agelaki, D. Mavroudis, J. Souglakos, S. Kakolyris, K. Kalbakis, N. Vardakis, D. Reppa, D. Hatzidaki, G. Samonis, V. Georgoulas: A dose escalation study of weekly docetaxel in patients with advanced solid tumors. *Cancer Chem Pharm* 46: 488-492, 2000.
  130. D. Mavroudis, A. Alexopoulos, N. Ziras, N. Malamos, Ch. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Tsavaris, A. Potamianou, G. Rigatos, V. Georgoulas: Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study. *Ann Oncol* 11: 1249-1254, 2000.
  131. AM. Dimopoulos, Ch. Papadimitriou, V. Georgoulas, L. Mouloupoulos, G. Aravantinos, D. Gika, S. Karpathios, St. Stamatelopoulos: Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long term results of a phase II multicenter study. *Gynecol Oncol* 78(1): 52-57, 2000.
  132. J. Vlachonkolis, M. Mavromanolakis, V. Georgoulas: Descriptive epidemiology of cancer in Crete, Greece, 1994. Part III: Urinary cancers. *J BUON* 5: 331-335, 2000.
  133. Ch. Kouroussis, S. Kakolyris, D. Mavroudis, N. Androulakis, K. Kalbakis, S. Agelaki, E. Sarra, J. Souglakos, M. Christodoulakis, G. Samonis, V. Georgoulas: A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. *Am J Clin Oncol* 24(4): 404-407, 2001.
  134. S. Kakolyris, J. Souglakos, Ch. Kouroussis, N. Androulakis, D. Mavroudis, K. Kalbakis, A. Kotsakis, N. Vardakis, M. Koukourakis, J. Romanos, V. Georgoulas: A dose-finding study of irinotecan (CPT-11) plus 4-day continuous 5-fluorouracil (5-FU) infusion in advanced colorectal cancer. *Oncology* 60(3): 207-213, 2001.

135. S. Kakolyris, E. Papadakis, X. Tsiadaki, C. Kalofonos, A. Rapti, M. Toubis, E. Bania, Ch. Kouroussis, K. Chainis, N. Androulakis, S. Agelaki, E. Sarra, N. Vardakis, V. Georgoulas: Docetaxel in combination with gemcitabine as second-line treatment in NSCLC. A multicenter phase II study. *Lung Cancer* 32(2): 179-187, 2001.
136. G.P. Stathopoulos, D. Mavroudis, N. Tsavaris, Ch. Kouroussis, G. Aravantinos, S. Agelaki, S. Kakolyris, S. Rigatos, S. Karabekios, V. Georgoulas: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for the pancreatic cancer. *Ann Oncol* 12: 101-103, 2001.
137. S. Kakolyris, D. Mavroudis, N. Tsavaris, J. Souglakos, P. Tsiadaki, K. Kalbakis, S. Agelaki, N. Androulakis, V. Georgoulas: Paclitaxel in combination with carboplatin as salvage treatment in small cell lung cancer (SCLC). A multicenter phase II study. *Ann Oncol* 12: 193-197, 2001.
138. D. Mavroudis, E. Papadakis, M. Veslemes, X. Tsiadaki, J. Stavrakakis, Ch. Kouroussis, S. Kakolyris, E. Bania, J. Jordanoglou, M. Agelidou, J. Vlachonikolis, V. Georgoulas: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small cell lung cancer. *Ann Oncol* 12: 463-470, 2001.
139. G. Samonis, M. Anatoliotaki, H. Apostolakou, S. Maraki, D. Mavroudis, V. Georgoulas: Transient Fungemia due to *Rhodotorula rubra* in a cancer patient. *Infection* 29: 173-176, 2001.
140. S. Agelaki, H. Bania, Ch. Kouroussis, G. Blazoyianakis, J. Souglakos, X. Tsiadaki, A. Harpidou, K. Kalbakis, A. Rapti, N. Androulakis, E. Sarra, V. Georgoulas, E. Papadakis: Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: Two parallel multicenter phase II trials. *Oncology* 60(3): 235-241, 2001.
141. V. Georgoulas: Docetaxel/Gemcitabine: Salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer. *Oncology* 15 (suppl 2): 18-24, 2001.
142. A. Alexopoulos, Ch. Kouroussis, N. Malamos, S. Kakolyris, K. Kalbakis, Ch. Kosmas, D. Mavroudis, S. Agelaki, J. Vlachonikolis, E. Sarra, G. Rigatos, V. Georgoulas: Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front line chemotherapy in metastatic breast cancer: a multicenter phase II study. *Ann Oncol* 12 (6): 793-798, 2001.

143. S. Agelaki, S. Kakolyris, Ph. Palamidas, G. Rigatos, Ch. Kouroussis, D. Mavroudis, K. Kalbakis, D. Hatzidaki, V. Georgoulis, A. Rapti: A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small cell lung cancer. *Lung Cancer* 34: 133-139, 2001.
144. V. Georgoulis, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, M. Veslemes, Ph. Palamidas, J. Vlachonikolis: Platinum-based or non-platinum-based chemotherapy in advanced non-small cell lung cancer? Results of a randomised multicenter trial. *Lancet* 357: 1478-1484, 2001.
145. Ch. Kouroussis, J. Souglakos, S. Kakolyris, D. Mavroudis, N. Malamos, K. Kalbakis, N. Androulakis, A. Agelaki, N. Vardakis, G. Samonis, V. Georgoulis: Oxaliplatin (L-OHP) in combination with infusional 5-fluoracil (5-FU) and leucovorin (LV) every two weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study. *Oncology* 61(1): 36-41, 2001.
146. S. Kakolyris, Ch. Kouroussis, J. Souglakos, D. Mavroudis, S. Agelaki, K. Kalbakis, N. Androulakis, N. Vardakis, L. Vamvakas, V. Georgoulis: A phase I clinical trial of topotecan given every two weeks in patients with refractory solid tumors. *Oncology* 61: 265-270, 2001.
147. P. Papakostas, Ch. Kouroussis, N. Androulakis, G. Samelis, G. Aravantinos, E. Sarra, J. Souglakos, S. Kakolyris, V. Georgoulis: First line chemotherapy with docetaxel for unresectable or metastatic carcinoma of biliary tract. A multicenter phase II study. *Eur J Cancer* 37(15): 1833-1838, 2001.
148. K. Kalbakis, Ch. Kouroussis, S. Kakolyris, D. Mavroudis, J. Souglakos, S. Agelaki, L. Vamvakas, M. Chistodoulakis, K. Stylianou, V. Georgoulis: Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with anthracycline and taxane refractory metastatic breast cancer (MBC). *Br J Cancer* 85(6): 798-802, 2001.
149. M. Koukourakis, A. Giatromanolaki, S. Kakolyris, E. Sivridis, V. Georgoulis, G. Fountzilas, I. Hickson, K. Gatter, A. Harris: Nuclear expression of human apurinic/apyrimidinic endonuclease in head and neck cancer is associated with resistance to chemo-radiotherapy and poorer outcome. *Int J Radiat Oncol* 50(1): 27-36, 2001.



150. V. Georgoulas, G. Scagliotti, V. Miller, J. Eckardt, J.Y. Douillard, C. Manegold: Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. *Sem Oncol* 28: 25-21, 2001.
151. S. Kakolyris, A. Giatromanolaki, M. Koukourakis, G. Powis, J. Souglakos, E. Sivridis, V. Georgoulas, K.C. Gatter, A.L. Harris: Thioredoxin expression associates with lymph node status and prognosis in early operable non small cell lung cancer (NSCLC). *Clin Cancer Res* 7(10): 3087-3091, 2001.
152. J. Janinis, M. Papadakou, G. Panagos, A. Panousaki, V. Georgoulas, D. Hatzidaki, D. Lefantzis, G. Dokianakis: Sequential chemotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced head and neck cancer. *Am J Clin Oncol* 24: 227-231, 2001
153. S. Kakolyris, A. Giatromanolaki, M. Koukourakis, L. Kaklamanis, CH. Kourousis, V. Bozionelou, V. Georgoulas, K.C. Gatter and A.L. Harris. Assesment of Vascular Maturation in Lung and Breast Carcinomas Using a Novel Basement Membrane Component, LH39. *Anticancer Res* 21: 4311-4316, 2001.
154. V. Georgoulas, G. Samonis, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, M. Veslemes, Th. Grigoratou, Ph. Palamidas, Ch. Kouroussis, D. Mavroudis, S. Kakolyris, Th. Giannakakis, J. Vlachonikolis: Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: Early results of a randomized trial. *Lung Cancer* 34: 47-51, 2001.
155. G. Samonis, M. Anatoliotaki, H. Apostolakou, J. Souglakos and V. Georgoulas: Fatal Septicemia and Meningitis due to *Morganella morganii* in a patient with Hodgkin's disease. *Scand J Infect Dis* 33: 553-555, 2001.
156. S. Kakolyris, Ch. Kouroussis, J. Souglakos, S. Agelaki, K. Kalbakis, N. Vardakis, L. Vamvakas, V. Georgoulas: Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). *Lung Cancer* 34: 71-76, 2001.
157. S. Agelaki, H. Bania, Ch. Kouroussis, G. Blazoyiannakis, J. Souglakos, X. Tsiafaki, K. Kalbakis, A. Rapti, N. Androulakis, V. Georgoulas, E. Papadakis: Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study. *Lung Cancer* 34 (suppl 4): 77-80, 2001.
158. A. E. Stathopoulou, K. C. Angelopoulou, M. V. Perraki, V. A. Georgoulas , N. A. Malamos and E. S. Lianidou. Quantitative RT-PCR Luminometric Hybridization assay

- with an RNA Internal standard for Cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. *Clin Biochem* 34: 651-659, 2001.
- 159.** L. Vamvakas, S. Kakolyris, Ch. Kouroussis, K. Kandilis, D. Mavroudis, N. Ziras, N. Androulakis, K. Kalbakis, E. Sarra, J. Souglakos, V. Georgoulis: Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: A multicenter phase II study. *Am J Clin Oncol* 25(1): 65-70, 2002.
  - 160.** Ch. Kouroussis, J. Souglakos, D. Mavroudis, S. Papadouris, S. Kakolyris, S. Agelaki, K. Kalbakis, Ch. Panopoulos, N. Vardakis, E. Sarra, V. Georgoulis: Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan pretreated patients with advanced colorectal cancer (ACC). *Am J Clin Oncol* 25: 627-631, 2002.
  - 161.** D. Mavroudis, Ch. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, G. Samonis, and V. Georgoulis: Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every two weeks in patients with advanced solid tumors. *Oncology* 62: 216-222, 2002.
  - 162.** I.G. Vlachonikolis, T.J. Aletra, V. Georgoulis: Incidence of breast cancer on Crete, 1994-1995. *Eur J Cancer* 38: 574-577, 2002.
  - 163.** J. Souglakos, D. Mavroudis, S. Kakolyris, Ch. Kouroussis, N. Vardakis, N. Androulakis, S. Agelaki, K. Kalbakis, D. Tsetis, N. Athanasiadis, G. Samonis, V. Georgoulis. A triplet combination with irinotecan (CPT-11) plus oxaliplatin (L-OHP) plus continuous infusion 5-fluorouracil (5FU) and leucovorin (LV) as first line treatment in metastatic colorectal cancer (MCC): a multicenter phase II trial *J Clin Oncol* 20 (11): 2651-2657, 2002.
  - 164.** C. Kosmas, S. Agelaki, Th. Giannakakis, D. Mavroudis, Ch. Kouroussis, K. Kalbakis, S. Papadouris, J. Souglakos, N. Malamos, V. Georgoulis: Phase I-II study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pre-treated advanced breast cancer. *Oncology* 62: 103-109, 2002.
  - 165.** J. Souglakos, A. Kostakis, Ch. Kouroussis, S. Kakolyris, D. Mavroudis, K. Kalbakis, S. Agelaki, J. Vlachonikolis, V. Georgoulis, G. Samonis. Non neutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. *Cancer* 65(6): 1326-1333, 2002.
  - 166.** S. Kakolyris, Ch. Kouroussis, M. Koukourakis, D. Mavroudis, K. Malas, N. Vardakis, V. Bozionelou, K. Kalbakis, V. Georgoulis. A dose-escalation study of Oxaliplatin and Vinorelbine in patients with advanced solid tumors. *Oncology* 63: 213-218, 2002.

167. D. Bafaloukos, H. Gogas, V. Georgoulis, E. Briassoulis, G. Fountzilias, E. Samantas, Ch. Kalofonos, D. Skarlos, A. Karabelis, P. Kosmidis: Temozolomide in combination with docetaxel in patients with advanced melanoma: A Phase II study of the Hellenic Cooperative Oncology Group. *J Clin Oncol* 20 (2): 420-425, 2002.
168. V. Georgoulis: Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. *Lung Cancer* 38: 61-66, 2002.
169. S. Kakolyris, J. Souglakos, Ch. Kouroussis, M. Koukourakis, K. Kalbakis, D. Mavroudis, N. Vardakis, V. Georgoulis: A Dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. *Anticancer Res* 22: 1891-1896, 2002.
170. V. Georgoulis: Docetaxel (Taxotere) in the treatment of non-small cell lung cancer. *Curr Med Chem* 9(8): 869-877, 2002.
171. N. Androulakis, Ch. Kouroussis, D. Mavroudis, S. Kakolyris, J. Souglakos, S. Agelaki, K. Kalbakis, K. Malas, A. Pallis, G. Samonis, V. Georgoulis: Phase I of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumors. *Eur J Cancer* 38: 1992-1997, 2002.
172. D. Mavroudis, M. Veslemes, Ch. Kouroussis, N. Tzanakis, E. Ferdoutsis, M. Toubis, P. Ziotopoulos, M. Agelidou, E. Tselepatiotis, K. Kalbakis, J. Souglakos, E. Magkanas, G. Samonis, V. Georgoulis : Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. *Lung Cancer* 38: 59-63, 2002.
173. A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, D. Reppa, V. Georgoulis: Molecular Detection of Cytokeratin-19 positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. *J Clin Oncol* 20 (16): 3404-3412, 2002.
174. M. Koukourakis, A. Giatromanolaki, Ch. Kouroussis, S. Kakolyris, E. Sivridis, C. Frangiadaki, G. Retalis, V. Georgoulis: Hypofractionated and accelerated radiotherapy with cytoprotection (Hypo ARC): A short, safe, and effective postoperative regimen for high-risk breast cancer patients. *Int J Radiat Oncol Biol Phys* 52(1): 144-55, 2002.
175. C. Gennatas, D. Mouratidou, N. Androulakis, V. Georgoulis, N. Tsavaris, M. Philippakis, E. Michailakis, C. Kalofonos, S. Mpesmpeas, J. Katsos, M. Tsitoura, G. Retalis, K.

- Mallas, D. Voros, C. Andreadis, G. Hatzistylianos, C. Pisiotis, D. Kamilarios, S. Kakolyris, V. Komporozos, D. Kannas, N. Legakis, T. Mpatakis, J. Ntamtsios, E. Papaevangelou, G. Peros, A. Photopoulos, A. Pouli, S. Prigouris, L. Samanidis, V. Sakellariou, V. Smyrniotis, G. Polymeneas, J. Vasiliou, A. Athanasiou, J. Papadimitriou: Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma. *Tumori* 88 (1): 32-36, 2002.
- 176.** Th. Giannakakis, S. Kakolyris, E. Theodoropoulos, Ch. Kouroussis, E. Michailakis, S. Papadouris, M. Tsitoura, K. Kalbakis, J. Souglakos, S. Agelaki, N. Vardakis, V. Georgoulis: A multicenter phase II study of docetaxel and carboplatin as front-line treatment in advanced non-small cell lung cancer. *Anticancer Res* 22: 3743, 2002.
- 177.** D. Mavroudis, A. Alexopoulos, N. Malamos, A. Ardavanis, C. Kandyliis, E. Stavrinidis, Ch. Kouroussis, S. Agelaki, N. Androulakis, V. Bozionelou, V. Georgoulis: Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. *Oncology* 64:207-212, 2003.
- 178.** D. Mavroudis, G. Pavlaku, G. Blazoyiannakis, M. Veslemes, F. Apostolopoulou, Ch. Kouroussis, S. Kakolyris, S. Agelaki, N. Androulakis, N. Vardakis, E. Magkanas, G. Samonis, V. Georgoulis : Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study *Lung Cancer* 39: 71-76, 2003.
- 179.** D. Mavroudis, P. Papas, Ch. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, G. Samonis, M. Marselos, V. Georgoulis : A dose escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. *Ann Oncol* 14: 304-312, 2003.
- 180.** E. de Bree, H. Rosing, J. H. Beijnen, J. Romanos, J. Michalakis, V. Georgoulis, D. Tsiftsis: Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. *Anti-Cancer Drugs* 14: 103-111, 2003.
- 181.** R. Paridaens, F. Van Aelst, V. Georgoulis, H. Samonning, S. Van Belle, C. Zielinski, H. Hausmaninger, P. Willemse, Y. Boudraa, J. Wildiers, C. Ramazeilees, N. Azli: A Randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. *Ann Oncol* 14: 433-440, 2003
- 182.** GP. Stathopoulos, SK. Rigatos, MA. Dimopoulos, Th. Giannakakis, G. Foutzilias, Ch. Kouroussis, D. Janninis, G. Aravantinos, N. Androulakis, S. Agelaki, JG. Stathopoulos, V.

- Georgoulas: Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: A multicenter phase II study of the Greek Cooperative group for Pancreatic Cancer. *Ann Oncol* 14: 388-394, 2003.
- 183.** Ch. Kouroussis, S. Agelaki, D. Mavroudis, S. Kakolyris, N. Androulakis, K. Kalbakis, J. Souglakos, K. Mallas, V. Bozionelou, A. Pallis, H. Adamtziki, V. Georgoulas: A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. *Anticancer Res* 23: 785-792, 2003.
- 184.** A. G. Pallis, D. Mavroudis, N. Androulakis, J. Souglakos, Ch. Kouroussis, V. Bozionellou, I.G. Vlachonikolis, V. Georgoulas: ZD 1839, a novel, oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. *Lung Cancer* 40: 301-307, 2003.
- 185.** J. Souglakos, N. Androulakis, D. Mavroudis, Ch. Kouroussis, S. Kakolyris, N. Vardakis, K. Kalbakis, A. Pallis, A. Ardavanis, Ch. Varveris, V. Georgoulas : A multicenter dose finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. *Int J Rad Oncol Biol Phys* 56: 1284-1287, 2003.
- 186.** N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, Ch. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, E. Lianidou, V. Georgoulas: Peripheral blood circulating cytokeratin-19 mRNA positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. *Ann Oncol* 14: 849-855, 2003.
- 187.** V. Georgoulas, A. Pallis, Ch. Kouroussis, A. Alexopoulos, A. Ardavanis, A. Agelidou, M. Agelidou, M. Toubis, S. Tzannes, G. Pavlaku, P. Ziotopoulos, E. Tselepatiotis, N. Samaras: Docetaxel versus docetaxel/cisplatin in patients with advanced non-small cell lung cancer: Preliminary analysis of a multicenter phase III study. *Clin Lung Cancer* 4: 288-293, 2003.
- 188.** E. de Bree, J. Romanos, J. Machalakis, V. Georgoulas, K. Relakis, J. Melissa, D. Tsiftis : Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel following cytoreductive surgery as second-line treatment for peritoneal carcinomatosis of gynecological malignancies. *Anticancer Res* 23: 3019-3028, 2003.
- 189.** A. Stathopoulou, D. Mavroudis, M. Perraki, S. Apostolaki, J. Vlachonikolis, E. Lianidou, V. Georgoulas: Molecular detection of cancer cells in the peripheral blood of patients with

- breast cancer comparison of CK-19, CEA and Maspin as detection markers. *Anticancer Res* 23: 1883-1890, 2003.
- 190.** S. Cascinu, V. Georgoulas, D. Kerr, T. Maughan, R. Labianca, M. Ychou: Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. *Ann Oncol* 14: 25-29, 2003.
- 191.** A. Stathopoulou, A. Gizi, M. Perraki, S. Apostolaki, N. Malamos, D. Mavroudis, V. Georgoulas, E. Lianidou: Real-time quantification of Ck-19 mRNA positive cells in peripheral blood of breast cancer patients using the lightcycler system. *Clin Cancer Res* 9: 5145-5151, 2003.
- 192.** G. Fountzilas, E. Razis, D. Tsavdaridis, M. Karina, S. Labropoulos, C. Christodoulou, D. Mavroudis, H. Gogas, V. Georgoulas, D. Skarlos: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the hellenic cooperative oncology group. *Clin Breast Cancer* 4: 120-125, 2003.
- 193.** G. Samonis, S. Maraki, Ch. Kouroussis, D. Mavroudis, V. Georgoulas: Salmonella enterica Pneumonia in a patient with lung cancer. *J Clin Microbiol* 41:5820-4822, 2003.
- 194.** S. Kakolyris, K. Amarantidis, O. Kougioumtzidou, V. Georgoulas: Assessment of vascular maturation using a new basement membrane epitope, LH 39. a new prognostic indicator in human neoplasia? *Recent Res Devel Cancer* 5: 175-184, 2003.
- 195.** S. Agelaki, K. Syrigos, Ch. Christophylakis, J. Boukovinas, J. Varthalitis, G. Pavlaku, A. Athanasiadis, Ch. Kouroussis, N. Vardakis, G. Maltezas, G. Milaki, V. Georgoulas: A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small cell lung cancer. *Oncology* 66: 192-196, 2004.
- 196.** Ch. Kouroussis, D. Mavroudis, S. Kakolyris, A. Voloudaki, K. Kalbakis, J. Souglakos, S. Agelaki, K. Malas V. Bozionellou, V. Georgoulas: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: Results of a dose-finding study. *Lung Cancer* 44:363-368, 2004.
- 197.** S. Agelaki, M. Veslemes, K. Syrigos, F. Palamidas, A. Polyzos, P. Papakotoulas, N. Kentepozidis, G. Milaki, N. Tzanakis, Ch. Kouroussis, L. Vamvakas, V. Georgoulas: A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. *Lung Cancer* 43: 329-333, 2004.
- 198.** G.P. Stathopoulos, K. Syrigos, A. Polyzos, G. Fountzilas, S.K. Rigatos, N. Ziras, A. Potamianou, I. Tsiakopoulos, N. Androulakis, G. Aravantinos, A. Athanasiadis, P.

- Papakotoulas, V. Georgoulas: Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup multicenter phase II study. *Ann Oncol* 15: 224-229, 2004.
- 199.** A. Giatromanolaki, M. Koukourakis, S. Kakolyris, D. Mavroudis, Ch. Kouroussis, Ch. Mavroudi, M. Perraki, E. Sivridis, V. Georgoulas: Assessment of “highly angiogenic and disseminated in the peripheral blood” (HAD) disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. *Int J Cancer* 108: 620-627, 2004
- 200.** S. Kakolyris, J. Souglakos, Ch. Kouroussis, N. Androulakis, G. Samonis, N. Vardakis, K. Amarantidis, S. Agelaki, D. Mavroudis, N. Xenidis, V. Georgoulas: A dose-escalating study of Oxaliplatin and Capecitabine (Xeloda) in patients with advanced solid tumors. *Oncology* 66: 253-259, 2004.
- 201.** G. Fountzilas, G. Stathopoulos, G. Kouvatseas, A. Polychronis, G. Klouvas, E. Samantas, N. Zamboglou, K. Kyriakou, A. Adamou, D. Pectasidis, T. Ekonomopoulos, H.P. Kalofonos, D. Bafaloukos, V. Georgoulas, E. Razis, D. Koukouras, V. Zombolas, P. Kosmidis, D. Skarlos, N. Pavlidis: Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. *Am J Clin Oncol* 27: 57-67, 2004
- 202.** K. Angelopoulou, T. Spiropoulou, A. Stathopoulou, D. Dimitroulopoulos, N. Malamos, V. Georgoulas, E. Paraskevas, E. Lianidou: Development of Highly Sensitive RT-PCR luminometric Hybridization assay for human telomerase reverse-transcriptase beta-plus transcript. *Anticancer Res* 23: 4821-4829, 2004.
- 203.** N. Androulakis, K. Syrigos, A. Polyzos, G. Aravantinos, G.P. Stathopoulos. N. Ziras, K. Malas, L. Vamvakas, V. Georgoulas: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study. *Cancer Invest* 23: 9-12, 2005.
- 204.** M. Anatoliotaki, V. Valatas, E. Mantadakis, H. Apostolakou, D. Mavroudis, V. Georgoulas, K.V. Roston, D. P. Kontogiannis, E. Galanakis, G. Samonis: Bloodstream infections in patients with solid tumors: Associated factors, microbial spectrum and outcome. *Infection* 32: 65-71, 2004.
- 205.** A. Keller, RG. Mennel, V. Georgoulas, JM. Nabholz, A. Erazo, A. Lluch, CL. Vogel, M. Kaufmann, G von Minckwitz, IC, Henderson, L. Alland, C. Tandler, and the Caelyx Breast Cancer Group: A randomized phase III trial of Caelyx<sup>TM</sup>/Doxil®/Doxil (Pegylated

- Liposomal Doxorubicin HCl) versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. *J Clin Oncol* 22: 3893-3901, 2004.
- 206.** D. Mavroudis, N. Malamos, A. Polyzos, Ch. Kouroussis, Ch. Christophilakis, I. Varthalitis, N. Androulakis, K. Kalbakis, G. Milaki, V. Georgoulas: Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: A multicenter phase II study. *Oncology* 67: 250-256, 2004.
- 207.** J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, A. Kotsakis, V. Georgoulas: Combination of irinotecan (CPT-11) plus Oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: A multicancer phase II trial. *Ann Oncol* 15: 1204-1209, 2004.
- 208.** V. Georgoulas, A. Ardavanis, A. Agelidou, M. Agelidou, V. Chandrinos, E. Tsaroucha, M. Toumbis, Ch. Kouroussis, K. Syrigos, A. Polyzos, N. Samaras, P. Papakotoulas, Ch. Christofilakis, N. Ziras, A. Alegakis: Docetaxel versus docetaxel plus cisplatin a front line treatment of patients with advanced non small cell lung cancer. A randomized, multicenter phase III trial. *J Clin Oncol* 22: 2602-2609, 2004.
- 209.** A. Cervantes, V. Georgoulas, A. Falcone: State of the art treatment for gastric cancer: future directions. *Eur J Cancer (suppl)* 2 (7): 40-47, 2004.
- 210.** V. Georgoulas, Ch. Kouroussis, A. Agelidou, I. Boukovinas, Ph. Palamidis, E. Stavriniadis, A. Polyzos, K. Syrigos, M. Veslemes, M. Toubis, A. Ardavanis, E. Tselepatiotis, I. Vlachonikolis : Irinotecan plus gemcitabine versus irinotecan for the second-line treatment of patients with advanced non-small cell lung cancer pretreated with docetaxel and cisplatin : A multicenter, randomized, phase II study. *Br J Cancer* 91: 482-488, 2004.
- 211.** V. Bozionellou, D. Mavroudis, M. Perraki, S. Apostolaki, E. Stathopoulos, A. Stathopoulou, E. Lianidou, V. Georgoulas: Trastuzumab (Herceptin) administration can effectively target chemotherapy-resistant cytokeratin-19 (CK-19) mRNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. *Clin Cancer Res* 10: 8185-8194, 2004.
- 212.** V. Georgoulas, A. Kalykaki: Clinical benefit from the combination of docetaxel plus cisplatin as first-line treatment in a patient with advanced non-small cell lung cancer (NSCLC). *Am J Oncol Rev* 3: 627-630, 2004.
- 213.** Ch. Kouroussis, K. Kalbakis, N. Androulakis, S. Agelaki, L. Vamvakas, K. Malas, J. Souglakos, N. Vardakis, V. Georgoulas: A dose escalation study of leucovorin (LV) and



- 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with cyclophosphamide (CPM) and vinorelbine (VNR) in pretreated patient with metastatic breast cancer (MBC). *Anticancer Res* 24: 4217-4222, 2004.
- 214.** K. Kalofonos, Ch. Kouroussis, M. Karamouzis, G. Iconomou, E. Tsiata, F. Tzorzidis, P. Megas, E. Lambiris, V. Georgoulas: A phase II study of docetaxel and epirubicin in advanced adult soft tissue sarcomas (STS) *Sarcoma* 8: 129-133, 2004.
- 215.** J. Souglakos, A. Pallis, S. Kakolyris, D. Mavroudis, N. Androulakis, Ch. Kouroussis, S. Agelaki, N. Xenidis, G. Milaki, V. Georgoulas: Combination of Irinotecan (CPT-11) plus bolus followed by continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI) as first line treatment for elderly patients with metastatic colorectal cancer (MCC): A phase II study. *Oncology* 69: 384-390, 2005.
- 216.** A. Apeossos, M. Mihalatos, I. Danielidis, G. Kallimanis, N.J. Agnantis, I.K. Triantafillidis, G. Fountzilas, P.A. Kosmidis, E. Razis, V. A. Georgoulas: hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients. *Br J Cancer* 92: 396-404, 2005.
- 217.** J. Souglakos, S. Kakolyris, N. Vardakis, N. Androulakis, D. Mavroudis, L. Vamvakas, Ch. Kouroussis, S. Agelaki, Z. Saridaki, V. Georgoulas: A dose escalating study of Oxaliplatin (L-OHP) and high dose weekly leucovorin (LV) and 5-fluorouracil (5FU) in patients with advanced solid tumors. *Cancer Invest* 23: 505-510, 2005.
- 218.** A. Polyzos, K. Syrigos, J. Stergiou, Ch. Panopoulos, A. Potamianou, L. Vamvakas, V. Georgoulas: Phase I trial of weekly docetaxel with a four hour weekly cisplatin administration in patients with advanced gastric carcinoma. *Cancer Chem Pharm* 55: 466-470, 2005.
- 219.** J. Souglakos, N. Vardakis, N. Androulakis, S. Kakolyris, Ch. Kouroussis, D. Mavroudis, A. Pallis, A. Agelaki, K. Kalbakis, V. Georgoulas : Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer : A phase II trial. *J BUON* 10: 47-52, 2005.
- 220.** A. Rapti, A. Agelidou, I. Stergiou, M. Agelidou, I. Nikolakopoulos, J. Varthalitis, A. Kalykaki, K. Chainis, N. Tzanakis, V. Georgoulas: Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: A multicentre phase II study. *Lung Cancer* 49: 241-244, 2005
- 221.** V. Georgoulas, A. Ardavanis, X. Tsiafaki, A. Agelidou, P. Mixalopoulou, O. Anagnostopoulou, P. Ziotopoulos, A. Toubis, K. Syrigos, N. Samaras, A. Polyzos, A. Christou, S. Kakolyris, Ch. Kouroussis, N. Androulakis, G. Samonis, D. Chatzidaki:

- Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial. *J Clin Oncol* 23:2937-2945, 2005.
- 222.** E. Stathopoulos, E. Sanidas, M. Kafousi, D. Mavroudis, J. Askoxylakis, V. Bozionelou, M. Perraki, D. Tsiftsis, V. Georgoulas: Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemocally negative axillary lymph nodes. *Ann Oncol* 16: 240-246, 2005
- 223.** G. Aravantinos, G. Fountzilias, P. Kosmidis, MA Dimopoulos, GP Stathopoulos, N Pavlidis, D. Bafaloukos, C. Papadimitriou, S. Karpathios, V. Georgoulas, P. Papakostas, HP Kalofonos, E. Grimani, DV Skarlos: Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology group (HeCOG) Study. *Ann Oncol* 16: 116-115, 2005.
- 224.** N. Tsakountakis, E. Sanidas, E. Stathopoulos, M. Kafousi, N. Anogiannaki, V. Georgoulas, D. Tsiftsis: Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status *BMC Women's Health* 5:1-9, 2005.
- 225.** N. Androulakis, V. Georgoulas: NSCLC-platinum or not. *Lung Cancer*. 47: 381-383, 2005.
- 226.** Ch. Kouroussis, N. Androulakis, L. Vamvakas, T. Kalykaki, S. Spiridonakou, N. Kentepozidis, Z. Saridaki, El. Xiropoulou, V. Georgoulas: Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors. *Oncology* 69: 202-207, 2005.
- 227.** C. Twelves, A. Wong, M. Nowacki, M. Abt, H. Buris III, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulas, F. Hussein, D. Jodrell, P. Koralewski, H. Kroning, J. maroon, N. Marschner, J. McKendrick, M. Pawlicki, r. Rosso, J. Schuller, J-F. Seitz, B. Stabuc, J. Tujakowski, G. VancHazel, J. Zaluski, W. Scheithauer: Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 352: 2696-2704, 2005.
- 228.** P. Ziotopoulos, N. Androulakis, E. Mylonaki, V. Chandrinos, E. Zachariadis, I. Boukovinas, A. Agelidou, N. Kentepozidis, M. Ignatiadis, A. Vossos, V. Georgoulas: Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. *Lung Cancer* 50: 115-122, 2005.
- 229.** V. Georgoulas, A. Agelidou, K. Syrigos, A. Rapti, M. Agelidou, J. Nikolakopoulos, A. Polyzos, A. Athanasiadis, E. Tselepatiotis, N. Androulakis, K. Kalbakis, G. Samonis, D.

- Mavroudis: Second-line treatment with irinotecan plus ciplatin versus cisplatin of patients with advanced non-small cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomized phase II study. *Br J Cancer* 93: 763-769, 2005.
- 230.** A. Pallis, V. Georgoulas: A patient with stage IV non-small cell lung cancer treated with docetaxel and gecitabine. *Am J Oncol Rev* 4: 534-538, 2005.
- 231.** S. Agelaki, V. Georgoulas: Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. *Exp Opinon Emerg Drugs* 10: 855-874, 2005.
- 232.** A. Potamianou, N. Androulakis, P. Papakotoulas, H. Toufexi, C. Latoufis, C. Kouroussis, C. Christofilakis, N. Xenidis, V. Georgoulas, A. Polyzos: Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer. A Multicenter Phase II Trial. *Oncology* 69: 348-353, 2005.
- 233.** M. Ignatiadis, D. Mavroudis, M. Veslemes, J. Boukovinas, K. Syrigos, M. Agelidou, A. Agelidou, A. Geroyianni, G. Pavlakou, E. Tselepatiotis. J. Nikolakopoulos, V. Georgoulas: Sequential versus alternating administration of cisplatin/etoposide and topotecan as first line treatment in extensive-stage small cell lung cancer: Preliminary results of a phase III trial of the Hellenic Oncology Research Group. *Clin Lung Cancer* 7:183-189, 2005.
- 234.** G.E. Chalkiadakis, K.G. Lasithiotakis, I.Petraqkis, C.Kouroussis, V. Georgoulas: Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case. *Int J Gynecol Cancer* 15: 1115-1119, 2005.
- 235.** A. Polyzos, C. Kosmas, H. Toufexi, N. Malamos, A. Lagadas, C. Kosmidis, P. Ginopoulos, N. Ziras, K. Kandilis, V. Georgoulas: Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. *Anticancer Res* 25: 3559-3564, 2005.
- 236.** S. Michalakis, S. Georgatos, J. Romanos, H. Koutala, V. Georgoulas, D. Tsiftsis, P. Theodoropoulos: Micromolar taxol, with or without hypothermia, induces mitotic catastrophe and cell necrosis. *Cancer Chem Pharm* 56: 615-622, 2005.
- 237.** N. Ziras, A. Potamianou, I. Varthalitis, K. Syrigos, S. Tsousis, I. Boukovinas, E. Tselepatiotis, Ch. Christofillakis, V. Georgoulas: Mutliceter phase II study of gemcitabine and Oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. *Oncology* 70: 106-114, 2006.

- 238.** L. Kaklamanis, M. Trichas, K. Amarantidis, N. Spathari, A. Micheli, A. Karayiannakis, E. Chatzaki, V. Georgoulas, S. Kakolyris: VEGF Expression in the colorectal adenoma-carcinoma sequence. *Oncol Res* 15: 445-451, 2006.
- 239.** A. Pallis, A. Agelidou, P. Papakotoulas, A. Tsaroucha, M. Agelidou, S. Agelaki, N. Androulakis, L. Vamvakas, A. Geroyianni, A. Kotsakis, N. Kentepozidis, V. Georgoulas: A multicentre phase II study of sequential vinorelbine and ciplain followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. *Lung Cancer* 52: 165-171, 2006.
- 240.** J. Souglakos, N. Androulakis, K. Syrigos, A. Polyzos, N. Ziras, A. Athanasiadis, S. Kakolyris, S. Tsousis, Ch. Kouroussis, L. Vamvakas, A. Kalykaki, G. Samonis, D. Mavroudis, V. Georgoulas: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) versus FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first line treatment in metastatic colorectal cancer (MCC): A multicenter randomized phase III trial from the hellenic oncology research group (HORG). *Br J Cancer* 94: 798-805, 2006.
- 241.** S. Kakolyris, A. Agelidou, N. Androulakis, E. Tsaroucha, Ch. Kouroussis, M. Agelidou, N. Karvounis, M. Veslemes, Ch. Christophylakis, A. Argyraki, A. Geroyianni, V. Georgoulas: Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma. *Lung Cancer* 53: 59-65, 2006.
- 242.** A. Ardavanis, D. Mavroudis, K. Kalbakis, N. Malamos, K. Syrigos, L. Vamvakas, A. Kotsakis, N. Kentepozidis, Ch. Kouroussis, S. Agelaki, V. Georgoulas : Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: A multicentre phase II study. *Cancer Chem Pharm* 58: 742-748, 2006.
- 243.** S. Koukouraki, L.G. Strauss, V. Georgoulas, M. Eisenhut, U. Haberkon, A. Dimitrakopoulou-Strauss: Ga-DOTATOC and F-FDG in patients with metastatic neuroendocrine tumors (NET) scheduled for Y-DOTATOC therapy. *J Nuclear Med* 33: 460-466, 2006.
- 244.** A. Stathopoulou, M. Ntoulia, M. Perraki, S. Apostolaki, D. Mavroudis, N. Malamos, V. Georgoulas, E. Lianidou: A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. *Int J Cancer* 119: 1654-1659, 2006.

- 245.** P. Markantonakis, P. Ziotopoulos, A. Agelidou, A. Polyzos, A. Ziras, V. Chandrinos, A. Vossos, A. Kalykaki, N. Androulakis, A. Geroyianni, V. Georgoulis: Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxanes-based regimen: A multicentre phase II study. *Lung Cancer* 53: 85-90, 2006.
- 246.** N. Xenidis, M. Perraki, M. Kafousi, S. Apostolaki, A. Stathopoulou, K. Kalbakis, N. Androulakis, Ch. Kouroussis, T. Pallis, Ch. Cristophylakis, K. Argyraki, E. Lianidou, S. Stahtopoulos, V. Georgoulis, D. Mavroudis: Predictive and prognostic value of peripheral blood cytokeratic-19 mRNA positive cells detected by real time PCR in node-negative breast cancer patients. *J Clin Oncol* 24: 3756-3762, 2006.
- 247.** A. Dimitrakopoulou-Strauss, V. Georgoulis, M. M. Eisenhut, F. Herth, S. Koukouraki, HR. Macke, U. Haberkorn, LG. Strauss: Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. *Eur J Nucl Med Mol Imaging* 33: 823-830, 2006.
- 248.** I. Boukovinas, N. Androulakis, L. Vamvakas, P. Papakotoulas, N. Ziras, A. Kalykaki, A. Kotsakis, I. Gioulmbasanis, D. Mavroudis, V. Georgoulis: Sequential gemcitabine and cisplatin followed by doxorubicin as first-line treatment of advanced urothelial carcinoma: a multicentre phase II study of the Hellenic Oncology research Group (HORG). *Ann Oncol* 17: 1687-692, 2006.
- 249.** J. Souglakos, L. Vamvakas, S. Apostolaki, M. Perraki, Z. Saridaki, I. Kazakou, A. Pallis, Ch. Kouroussis, N. Androulakis, K. Kalbakis, G. Millaki, D. Mavroudis, V. Georgoulis: Central nervous system (CNS) relapse in patients with breast cancer is associated with advanced stages, the presence of circulating occult tumor cells and the HER2/neu status. *Breast Cancer Res* 8: R36, 2006.
- 250.** S. Kakolyris, K. Kalbakis, A. Potamianou, N. Malamos, L. Vamvakas, Ch. Christophyllakis, E. Tselepatiotis, S. Giassas, D. Mavroudis, K. Amarantidis, V. Georgoulis: Salvage chemotherapy with gemcitabine and oxaliplatin (GEMOX regimen) in heavily pretreated patients with metastatic breast cancer (MBC): A multicenter phase II study. *Oncology* 70: 273-279, 2006.
- 251.** D. Mavroudis, I. Bolonakis, S. Cornet, G. Myllaki, P. Kanellou, A. Galanis, Ch. Christophyllakis, I. Nikoloudi, J. Menez, I. Miconnet, M. Niniraki, M. Spyropoulou, P. Cordopatis, K. Kosmatopoulos, V. Georgoulis: A Phase I study of the optimized cryptic peptide TERT<sub>572Y</sub> in patients with advanced malignancies. *Oncology* 70: 306-314, 2006.

- 252.** N. Androulakis, G. Aravantinos, K. Syrigos, A. Polyzos, N. Ziras, E. Tselepatiotis, G. Samonis, N. Kentepozidis, S. Giassas, L. Vamvakas, V. Georgoulis: Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: A multicenter phase II study. *Oncology* 70: 280-284, 2006.
- 253.** D. Hatzidaki, S. Agelaki, D. Mavroudis, I. Vlachonikolis, A. Alegakis, V. Georgoulis: A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced non-small cell lung cancer. *Clin Lung Cancer* 8: 49-55, 2006.
- 254.** M. Ntoulia, A. Stathopoulou, M. Ignatiadis, N. Malamos, D. Mavroudis, V. Georgoulis and E.S. Lianidou: Detection of Mammaglobin A-mRNA positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. *Clin Biochem* 39: 879-887, 2006.
- 255.** M. Ntoulia, L. Kaklamanis, C. Valavanis, M. Kafousi, E. Stathopoulos, P. Arapantoni, D. Mavroudis, V. Georgoulis, E. S. Lianidou: HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. *Clin Biochem* 39: 942-946, 2006.
- 256.** E. de Bree, H. Rosing, J. Romanos, K. Relakis, P.A. Theodoropoulos, J.H. Beijnen, V. Georgoulis, D.D. Tsiftsis: Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. *Eur J Surg Oncol* 32: 666-760, 2006.
- 257.** G.P. Stathopoulos, K. Syrigos, G. Aravantinos, A. Polyzos, P. Papakotoulas, g. Fountzilias, A. Potamianou, N. Ziras, J Boukovinas, J. Varthalitis, N. Androulakis, A. Kotsakis, G. Samonis, V. Georgoulis: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. *Br J Cancer* 95: 587-592, 2006.
- 258.** AG. Pallis, Ch. Christofillakis, E. Tselepatiotis, S. Agelaki, L. Vamvakas, J. Souglakos, N. Vardakis, A. Kalykaki, A. Kotsakis, A. Argiraki, D. Mavroudis, V. Georgoulis: Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial. *Lung Cancer* 55: 101-107, 2006.
- 259.** A. Chan, M. Martin, M. Untch, M. Gil Gil, V. Guillem-Porta, M. Wojtukiewicz, P. Kellokumpu-Lehtinen, HL. Sommer, V. Georgoulis, N. Batteli, M. Pawlicki, D. Aubert, T. Bourlard, J. Gasmi, L. Petruzelka: Long term survival benefit of vinorelbine

- (Navelbine) and trastuzumab (Herceptin) as first-line therapy for HER2-positive metastatic breast cancer patients: An international phase II study. *Br J Cancer* 95: 788-793, 2006.
- 260.** S. Kakolyris, N. Ziras, L. Vamvakas, J. Varthalitis, P. Papakotoulas, N. Vardakis, A. Kalykaki, K. Amatantidis, V. Georgoulas: Gemcitaine plus Oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II study. *Lung Cancer* 54: 347-352, 2006.
- 261.** P. Pappas, D. Mavroudis, M. Nikolaidou, V. Georgoulas, M. Marselos: Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. *Anti-Cancer Drugs* 17: 1185-1191, 2006.
- 262.** A. Karampeazis, L. Vamvakas, S. Agelaki, N. Kentepozidis, E. Papadimitraki, I. Gioulbasanis, N. Vardakis, M. Ignatiadis, D. Mavroudis, V. Georgoulas: A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors *Oncology* 71: 347-353, 2006.
- 263.** A. Kotsakis, Ch. Kouroussis, N. Androulakis, S. Agelaki, K. Kalbakis, L. Vamvakas, N. Vardakis, A. Kalykaki, A. Polyzos, V. Georgoulas, D. Mavroudis: A Dose Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors. *Oncology* 71: 190-196, 2006.
- 264.** A. Kalykaki, L. Vamvakas, S. Agelaki, K. Kalbakis, N. Vardakis, G. Sfakiotaki, M. Ignatiadis, Z. Saridaki, A. Karabeazis, D. Mavroudis, V. Georgoulas: A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors. *Oncology* 71: 197-203, 2006.
- 265.** M. Ignatiadis, A. Polyzos, GP. Stathopoulos, E. Tselepatiotis, Ch. Christophylakis, K. Kalbakis, L. Vamvakas, A. Kotsakis, A. Potamianou, V. Georgoulas: A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. *Oncology* 71: 159-163, 2006.
- 266.** J. Souglakos, A. Kalykaki, L. Vamvakas, N. Androulakis, K. Kalbakis, S. Agelaki, N. Vardakis, M. Tzardi, A. Kotsakis, J. Gioulbasanis, D. Tsetis, G. Sfakiotaki, D. Hatzidaki, D. Mavroudis, V. Georgoulas: Phase II study Capecitabine and Oxaliplatin (CAPOX) plus Cetuximab is an effective treatment for patients with metastatic colorectal cancer who progressed after oxaliplatin- based chemotherapy. *Ann Oncol* 18: 305-310, 2007.
- 267.** G. Kallergi, D. Mavroudis, V. Georgoulas, C. Stournaras: Phosphorylation of FAK, PI-3K and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells. *Mol Med* 13: 79-88, 2007.

- 268.** S. Apostolaki, M. Perraki, A. Pallis, V. Bozionelou, S. Agelaki, P. Kanellou, A. Kotsakis, E. Politaki, K. Kalbakis, A. Kalykaki, L. Vamvakas, V. Georgoulis, D. Mavroudis: Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. *Ann Oncol* 18: 851-858, 2007.
- 269.** J. Michalakis, S. Georgatos, E. de Bree, H. Polioutaki, J. Romanos, V. Georgoulis, D. Tsiftsis, P. Theodoropoulos: Short- term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long term inhibition of cell proliferation and cell death in vitro. *Ann Surg Oncol* 14: 1220-1228, 2007.
- 270.** J. Souglakos, N. Vardakis, N. Androulakis, S. Kakolyris, C. Kouroussis, D. Mavroudis, A. Pallis, A. Agelaki, K. Kalbakis, V. Georgoulis: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial. *Dig Dis* 25:100-5, 2007.
- 271.** A. Koutsopoulos, D. Mavroudis, K. Dambaki, J. Souglakos, E. Tzortzaki, J. Drositis, G. Delides, V. Georgoulis, E. Stathopoulos: Simultaneous expression of c-erbB-1, c-erbB-2, cerbB-3 and c-erbB-4 receptors in non small cell lung carcinomas. *Lung Cancer* 57:193-200, 2007.
- 272.** E. Bolonaki, A. Kotsakis, E. Papadimitraki, D. Agouraki, G. Konsolakis, A. Vagia, Ch. Christophylakis, E. Nikoloudi, E. Magganas, A. Galanis, P. Cordopatis, K. Kosmatopoulos, V. Georgoulis, D. Mavroudis. Vaccination of patients with advanced non-small cell lung cancer with an optimized cryptic hTERT peptide (Vx-001) *J Clin Oncol* 25: 2727-2734, 2007.
- 273.** A. Kouloubinis, L. Kaklamanis, N. Ziras, S. Sofroniadou, K. Makaritsis, S. Adamopoulos, I. Revela, A. Athanasiou, D. Mavroudis, V. Georgoulis: ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. *Int J Cardiol* 122: 195-201, 2007.
- 274.** N. Xenidis, V. Markos, S. Apostolaki, M. Perraki, A. Pallis, G. Sfakiotaki, D. Papadatos-Pastos, L. Kalmanti, M. Kafousi, E. Stathopoulos, S. Kakolyris, D. Mavroudis, V. Georgoulis: Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. *Ann Oncol* 18: 1623-1631, 2007.
- 275.** I. Gkioulbasanis, J. Souglakos, N. Vardakis, A. Kotsakis, Z. Saridaki, N. Kentepozidis, A. Polyzos, S. Giassas, M. Ignatiadis, V. Bozionelou, C. Christophylakis, V. Georgoulis



- Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract. *J BUON* 12: 197-202, 2007.
- 276.** V Bozionelou, L Vamvakas, P Pappas, S Agelaki, N Androulakis, A Kalykaki, M. Nikolaidou, N Kentepozidis, S Giassas, M Marselos, V Georgoulis, D Mavroudis: A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumors *Br J Cancer* 97: 43-49, 2007.
- 277.** Ch. Emmanouilides, G. Sfakiotaki, N. Androulakis, K. Kalbakis, Ch. Christophylakis, A. Kalykaki, L. Vamvakas, A. Kotsakis, S. Agelaki, E. Diamandidou, N. Touroutoglou, A. Chatzidakis, V. Georgoulis, D. Mavroudis, J.Souglakos: Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study *BMC* 7: 91, 2007.
- 278.** Z. Saridaki, V. Bozionelou, N. Kentepozidis, A. Kotsakis, N. Vardakis, A. Kalykaki, I. Gioulbasanis, A. Karabeazis, L. Vamvakas, V. Georgoulis, D. Mavroudis: A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors. *Oncology* 72: 45-50, 2007.
- 279.** N. Maniadakis, V. Fragoulakis, A. Pallis, P. Prezarakos, V. Georgoulis : Economic evaluation of docetaxel/gemcitabine versus docetaxel as front line treatment of patients with advanced/metastatic non small cell lung cancer in Greece. *Lung Cancer* 58: 275-281, 2007.
- 280.** N. Maniadakis, V. Fragoulakis, A. Pallis, P. Prezarakos, V. Georgoulis : Economic analysis of a multicenter, randomized, phase III trial comparing irinotecan, oxaliplatin, folinic acid (FOLFOXIRI) and 5-fluorouracil (FOLFIRI) with irinotecan, folinic acid and 5-fluorouracil in patients with metastatic colorectal cancer in Greece. *Curr Clin Med Res Opin* 23: 2251-2257, 2007.
- 281.** M. Ignatiadis, N. Xenidis, M. Perrki, S. Apostolaki, E. Politaki, M. Kafousi, E. Stathopoulos, A. Stathopoulou, E. Lianidou, G. Chlouverakis, C. Sotiriou, V. Georgoulis, D. Mavroudis: Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. *J Clin Oncol* 25: 5194-5202, 2007.

- 282.** G. Kallergi, S. Agelaki, H. Markomanolakis, V. Georgoulas, Ch. Stournaras: Activation of FAK/P13K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cell. *Cell Physiol Biochem* 20: 977-986, 2007.
- 283.** JY Douillard, S. Laporte, F. Fossella, V. Georgoulas, JL Pujol, K. Kubota, A. Monnier, S. Kudoh, JE Rubio, M. Cucherat: Comparison of docetaxel and vinca alkaloid based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials *J Thorac Oncol* 2: 939-946, 2007.
- 284.** B. Nordlinger, E. Van Cutsem, P. Rougier, CH. Kohne, M. Ychou, A. Sobrero, R. Adam, D. Arvidsson, A. Carrato, V. Georgoulas, F. Giuliante, B. Glimelius, M. Golling, T. Gruenberger, J. Tabernero, H. Wasan, G. Poston; on behalf of European Colorectal Metastases Treatment Group: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. *Eur J Cancer*. 43: 2037-2045, 2007.
- 285.** A.G. Pallis, A. Voutsina, Ar. Kalikaki, J. Souglakos, E. Briasoulis, S. Murray, A. Koutsopoulos, M. Tripaki, E. Stathopoulos, D. Mavroudis, V. Georgoulas: Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. *Br J Cancer* 97: 1560–1566, 2007
- 286.** M. Ignatiadis, M. Perraki, S. Apostolaki, E. Politaki, N. Xenidis, M. Kafousi, E. Stathopoulos, E. Lianidou, C. Sotiriou, V. Georgoulas, D. Mavroudis: Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. *Clin Breast Cancer* 7: 883-889, 2007.
- 287.** S. Kakolyris, J. Souglakos, A. Polyzos, A. Ardavanis, N. Ziras, A. Athanasiadis, I. Varthalitis, K. Amarantidis, S. Tsousis, L. Vamvakas, N. Vardakis, V. Georgoulas: Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every 2 Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Front-Line Therapy: A Multicenter Phase II Study. *Oncology* 74: 31-36, 2008.
- 288.** V. Georgoulas, N. Androulakis, A. Kotsakis, D. Hatzidaki, K. Syrigos, A. Polyzis, A. Agelidou, I. Varthalitis, N. Ziras, M. Agelidou, V. Chandrinos, I. Boukovinas, A. Geroyianni, L. Vamvakas, D. Mavroudis: Docetaxel versus docetaxel plus gemcitabine as

- front line treatment of patients with advanced non-small cell lung cancer: A randomized. Multicenter phase III trial. *Lung Cancer* 59: 57-63, 2008.
- 289.** M. Ignatiadis, V. Georgoulas, D. Mavroudis: Circulating tumor cells in breast cancer. *Curr Opin Obst Gyn* 20: 55-60, 2008.
- 290.** K. Kalbakis, P. Pappas, C. Kouroussis, L. Vamvakas, A. Kalykaki, N. Vardakis, M. Nikolaidou, M. Marselos, V. Georgoulas, D. Mavroudis: A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. *Cancer Chemoth Pharm* 62: 449-456, 2008.
- 291.** A. Kalykaki, P. Papakotoulas, S. Tsousis, I. Boukovinas, L. Vamvakas, A. Kotsakis, N. Vardakis, P. Papadopoulou, V. Georgoulas, D. Mavroudis: Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: A multicentr phase II study of the Hellenic Oncology Research Group (HORG). *Anticancer Research* 28: 495-500, 2008.
- 292.** E. Saloustros, D. Mavroudis, V. Georgoulas: Paclitaxel versus docetaxel in the treatment of breast cancer. *Expert Opinion in Pharmacotherapy* 90: 2603-2616, 2008.
- 293.** M. Ignatiadis, G. Kallergi, M. Ntoulia, M. Perraki, S. Apostolaki, M. Kafousi, G. Chlouverakis, E. Stathopoulos, E. Lianidou, V. Georgoulas, D. Mavroudis: Prognostic value of the molecular detection of circulating tumor cells using a multi-marker RT-PCR assay for cytokeratin 19, mammaglobin A and HER2 in early breast cancer. *Clinical Cancer Res* 14:2593-2600, 2008.
- 294.** A.G. Pallis, A. Polyzos, I. Boukovinas, A. Agelidou, X.Tsiafaki, M. Agelidou, G. Pavlakou, V.Chandrinou, S. Kakolyris, Ch. Christophyllakis, N. Kentepozidis, S. Giassas, N. Androulakis, S. Agelaki, V. Georgoulas: Pooled analysis of Elderly patients with non-small-cell lung cancer treated with front line docetaxel/gemcitabine regimen: The Hellenic Oncology Research Group Experience. *J Thoracic Oncology* 3: 505-510, 2008.
- 295.** J. Souglakos, I. Boukovinas, M. Taron, P. Mendez, D. Mavroudis, M. Tripaki, D. Hatzidaki, A. Koutsopoulos E. Stathopoulos, V. Georgoulas, R. Rosell: Ribonucleotide Reductase (RR) subunits M1 and M2 mRNA expression levels are associated with clinical outcomes of patients with lung adenocarcinomas treated with docetaxel/gemcitabine chemotherapy. *Br J Cancer* 98: 1710-1715, 2008.
- 296.** A.G. Pallis, S. Agelaki, S. Kakolyris, A. Kotsakis, A. Kalykaki, N. Vardakis, P. Papakotoulas, A. Agelidou, A. Geroyianni, M. Agelidou, D. Hatzidaki, D. Mavroudis, V.

- Georgoulis: Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small-cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. *Lung Cancer* 62: 356-363, 2008.
- 297.** GP. Stathopoulos, N. Androulakis, I. Souglakos, J. Stathopoulos, V. Georgoulis: Present treatment and future expectations in advanced pancreatic cancer. *Anticancer Res* 28: 1303-1308, 2008.
- 298.** M. Ignatiadis, Ch. Sotiriou, V. Georgoulis, D. Mavroudis: Different prognostic value of the detection of peripheral blood CK-19mRNA positive cells in early breast cancer subtypes: Discussion of three cases. *The American Journal of Hematology/Oncology* 7: 208-210, 2008.
- 299.** E. Saloustros, V. Georgoulis: Docetaxel in the treatment of advanced non small cell lung cancer. *Expert Review of Anticancer Therapy* 8:1207-1222, 2008.
- 300.** A. Kalikaki, A. Koutsopoulos, M. Trypaki, J. Souglakos, E. Stathopoulos, V. Georgoulis, D. Mavroudis, A. Voutsina: Comparison of EGFR and K-RAS gene status between primary tumor and corresponding metastases in NSCLC. *Br J Cancer* 99: 923-929, 2008.
- 301.** I. Gioulbasanis, Z. Saridaki, A. Kalykaki, L. Vamvakas, K. Kalbakis, M. Ignatiadis, K. Amarantidis, S. Kakolyris, V. Georgoulis, D. Mavroudis: Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. *Anticancer Res* 28 (5B): 3019-3025, 2008.
- 302.** G. Kallergi, S. Agelaki, A. Kalykaki, Ch. Stournaras, D. Mavroudis, V. Georgoulis: Phosphorylated EGFR and PI-eK/Akt signalling kinases are expressed in circulating tumor cell of breast cancer patients. *Breast Cancer Res* 10: R80, 2008.
- 303.** M. Ignatiadis, V. Georgoulis, D. Mavroudis: Micrometastatic disease in breast cancer: clinical implications. *European J Cancer* 44: 2726-2736, 2008.
- 304.** A. Markou, E. Tsaroucha, L. Kaklamanis, M. Fotinou, V. Georgoulis, E. Lianidou: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. *Clinical Chemistry* 54: 1696-1704, 2008.
- 305.** I. Boukovinas, Ch. Papadaki, P. Mendez, M. Taton, D. Mavroudis, A. Koutsopoulos, M. Sanchez-Ronco, J.J. Sanchez, M. Trypaki, E. Stathopoulos, V. Georgoulis, R. Rosell, J. Souglakos: Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical

- response to first-line gemcitabine plus Docetaxel in non-small cell lung cancer patients. *PLOS* 3(11):e3695, 2008.
- 306.** I. Boukovinas, J. Souglakos, D. Hatzidaki, S. Kakolyris, N. Ziras, L. Vamvakas, A. Polyzos, A. Gerogianni, A. Agelidou, S. Agelaki, K. Kalbakis, A. Kotsakis, D. Mavroudis, V. Georgoulas: Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study. *Lung Cancer* 63: 77-82, 2008.
  - 307.** S. Apostolaki, M. Perraki, G. Kallergi, M. Kafousi, S. Papadopoulolos, A. Kotsakis, A. Pallis, N. Xenidis, L. Kalmanti, K. Kalbakis, S. Agelaki, S. A. Kalykaki, Ch. Stournaras, E. Stathopoulos, V. Georgoulas, D. Mavroudis: Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. *Breast Cancer Res Treat* 117:525-534, 2009.
  - 308.** M. Kioulafa, L. Kaklamanis, E. Stathopoulos, D. Mavroudis, V. Georgoulas, ES Lianidou: Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. *Ann Oncol* 20: 1020-1025, 2009.
  - 309.** A. Kalikaki, M. Kanaki, H. Vassalou, J. Souglakos, A. Voutsina, V. Georgoulas, D. Mavroudis: DNA repair gene polymorphisms predict favorable clinical outcome in advanced Non-Small Cell Lung Cancer. *Clinical Lung Cancer* 10: 118-123, 2009.
  - 310.** V. Bozionelou, K. Kalbakis, L. Vamvakas, S. Agelaki, N. Androulakis, A. Kalykaki, V. Georgoulas, D. Mavroudis: A phase I trial of Gemcitabine, Docetaxel and Carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. *Cancer Chem Pharm* 64: 785-791, 2009.
  - 311.** L. Vamvakas, E. Saloustros, A. Karampeazis, V. Georgoulas: Advanced non small cell lung cancer in the elderly. *Clinical Lung Cancer* 10: 158-167, 2009.
  - 312.** Ch. Papadaki, D. Mavroudis, M. Trypaki, A. Koutsopoulos, E. Stathopoulos, D. Hatzidaki, E. Tsakalaki, V. Georgoulas, J. Souglakos: Tumoral expression of TXR1 and TSP1 predict overall survival of patients with lung adenocarcinoma treated with first line Docetaxel – Gemcitabine regimen. *Clin Cancer Res* 15: 3827-3833, 2009.
  - 313.** Z. Saridaki, P. Pappas, J. Souglakos, M. Nikolaidou, N. Vardakis, A. Kotsakis, M. Marselos, V. Georgoulas, D. Mavroudis: A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. *Cancer Chemoth Pharm* 65: 121-128, 2009.

- 314.** M. Kioulafa, L. Kaklamanis, D. Mavroudis, V. Georgoulas, ES. Lianidou: Prognostic significance of RASSF1A promoter methylation in operable breast cancer. *Clin Biochem* 42: 970-975, 2009.
- 315.** S. Agelaki, M. Spiliotaki, H. Markomanolaki, G. Kallergi, D. Mavroudis, V. Georgoulas, C. Stournaras C: Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. *Cancer Biol Ther* 8:1470-1477, 2009.
- 316.** S. Koukouli, A. Stamou, A. Alegakis, V. Georgoulas, G. Samonis: Psychometric properties of the QLQ-C30 (version 3.0) in a sample of ambulatory Cretan cancer patients. *Eur J Cancer* 18: 447-456, 2009.
- 317.** N. Xenidis, M. Ignatiadis, S. Apostolaki, M. Perraki, K. Kalbakis, S. Agelaki, E. Stathopoulos, G. Chlouverakis, E. Lianidou, S. Kakolyris, V. Georgoulas, D. Mavroudis: Cytokeratin-19 mRNA-positive circulating tumor cell after adjuvant chemotherapy in patients with early breast cancer: Evaluation of their clinical relevance. *J Clin Oncol* 27: 2177-2184, 2009.
- 318.** Ch. Kouroussis, L. Vamvakas, N. Vardakis, A. Kotsakis, A. Kalykaki, K. Kalbakis, Z. Saridaki, N. Kentepozidis, S. Giassas, V. Georgoulas: Continuous administration of daily low dose of temozolomide in pre-treated patients with advanced non-small cell lung cancer: A phase II study *Oncology* 76: 112-117, 2009.
- 319.** A. Pallis, A. Agelidou, S. Agelaki, I. Varthalitis, G. Pavlakou, A. Gerogianni, P. Papakotoulas, A. Rapti, V. Chandrinos, Ch. Christophyllakis, V. Georgoulas: A multicenter randomized phase II study of the irinotecan/gemcitabine doublet, versus irinotecan monotherapy in previously treated patients with extensive stage small cell lung cancer. *Lung Cancer* 65: 187-191, 2009.
- 320.** A. Daskalaki, S. Agelaki, M. Perraki, S. Apostolaki, N. Xenidis, E. Stathopoulos, E. Kontopodis, D. Hatzidaki, D. Mavroudis, V. Georgoulas: Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. *Br J Cancer* 101: 589-597, 2009
- 321.** A. Polyzos, N. Malamos, I. Boukovinas, A. Adamou, N. Ziras, K. Kalbakis, S. Kakolyris, K. Syrigos, P. Papakotoulas, C. Kouroussis, N. Karvounis, L. Vamvakas, C. Christophyllakis, A. Athanasiadis, I. Varthalitis, V. Georgoulas, D. Mavroudis: FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized

- study of the Hellenic Oncology Research Group (HORG). *Breast Cancer Res Treat* 119: 95-104, 2009
- 322.** J. Souglakos, J. Philips, R. Wang, S. Marwah, M. Silver, M. Tzardi, J. Silver, S. Ogino, S. Hooshmand, E. Kwak, E. Freed, JA Meyerhardt, Z. Saridaki, V. Georgoulas, D. Finkelstein, CS Fuchs, MH Kulke, RA Shivdasani: Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. *Br J Cancer* 101: 465-472, 2009
- 323.** G. Kallergi, H. Markomanolaki, V. Giannoukarakaki, MA. Papadaki, A. Strati, ES. Lianidou, V. Georgoulas, D. Mavroudis, S. Agelaki: Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. *Breast Cancer Res* 11: R84, 2009.
- 324.** M. Kioulafa, I. Balkouranidou, G. Sotiropoulou, L. Kaklamanis, D. Mavroudis, V. Georgoulas, ES Lianidou: Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. *Int J Cancer* 125: 2887-2892, 2009.
- 325.** PA Theodoropoulos, H Polioudaki, S Agelaki, G Kallergi, Z Saridaki, D Mavroudis, V Georgoulas: Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. *Cancer Lett* 288: 99-106, 2010.
- 326.** Z. Giannousi, I. Manaras, V. Georgoulas, G. Samonis: Illness perceptions in Greek patients with cancer: a validation of the Revised-Illness Perception Questionnaire. *Psychooncology* 19: 85-92, 2010.
- 327.** D. Mavroudis, P. Papakotoulas, A. Ardavanis, K. Syrigos, S. Kakolyris, N. Ziras, C. Kouroussis, N. Malamos, A. Polyzos, C. Christophyllakis, N. Kentepozidis, V. Georgoulas V: Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. *Ann Oncol* 21: 48-54, 2010.
- 328.** A. Valachis, D. Mauri, NP Polyzos, D. Mavroudis, V. Georgoulas, G. Casazza: Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. *Crit Rev Oncol Hematol* 73: 220-227, 2010.
- 329.** L. Vamvakas, A. Athanasiadis, A. Karampeazis, S. Kakolyris, A. Polyzos, C. Kouroussis, N. Ziras, K. Kalbakis, V. Georgoulas, J. Souglakos J: Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). *Crit Rev Oncol Hematol* 76: 61-70, 2010.

- 330.** S. Agelaki, D. Hatzidaki, A. Kotsakis, P. Papakotoulas, A. Polyzos, N. Ziras, I. Gioulbasanis, A. Karampeazis, A. Agelidou, X. Tsiadaki, V. Chandrinou, M. Lerikou, V. Georgoulas: Non-platinum-based first-line followed by platinum-based second line chemotherapy of the reverse sequence in patients with advanced non-small cell lung cancer (NSCLC). A retrospective analysis by Lung Cancer Group of the Hellenic Oncology Research Group (HORG). *Oncology* 78: 229-236, 2010.
- 331.** E. Saloustros, I. Zaganas, M. Mavridis, L. Vamvakas, A. Plaitakis, V. Georgoulas, D. Mavroudis: Anti-CV2 associated cerebellar degeneration after complete response to chemotherapy of head and neck carcinoma. *J Neuro-Oncology* 97: 291-294, 2010.
- 332.** A. Kalikaki, A. Koutsopoulos, D. Hatzidaki, M. Trypaki, E. Kontopodis, E. Stathopoulos, D. Mavroudis, V. Georgoulas, A. Voutsina: Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. *Lung Cancer* 69: 110-115, 2010.
- 333.** N. Xenidis, A. Kotsakis, A. Kalykaki, C. Christophyllakis, S. Giassas, N. Kentepozidis, A. Polyzos, L. Chelis, N. Vardakis, L. Vamvakas, V. Georgoulas, S. Kakolyris: Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. *Lung Cancer* 68: 450-454, 2010.
- 334.** N. Maniadas, V. Fragoulakis, AG. Pallis, E. Simou, V. Georgoulas: Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. *Ann Oncol* 21: 1462-1467, 2010.
- 335.** A. Valachis, NP. Polyzos, NA. Patsopoulos, V. Georgoulas, D. Mavroudis, D. Mauri: Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer Res Treat* 122: 1-7, 2010.
- 336.** Z. Saridaki, V. Georgoulas, J. Souglakos: Mechanisms of resistance to anti-EFGR monoclonal antibodies treatment in metastatic colorectal cancer. *World J Gastroenterology* 16: 1177-1187, 2010.
- 337.** Z. Saridaki, D. Papadatos-Pastos, M. Tzardi, D. Mavroudis, E. Bairaktari, H. Arvanity, E. Stathopoulos, V. Georgoulas, J. Souglakos: BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal (mCRC) patients' outcome. *Br J Cancer* 102: 1762-1768, 2010.



- 338.** O. Katopodis, A. Polyzos, N. Kentepozidis, S. Giassas, M. Rovithi, V. Bozionelou, K. Kalbakis, L. Vamvakas, D. Mavroudis, V. Georgoulis: Second line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable, adenocarcinoma of pancreas: The final results of a phase II trial. *Cancer Chem Pharm* 67: 361-368, 2010.
- 339.** Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulis V, Casazza G: Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. *J Natl Compr Canc Netw* 8: 279-286, 2010.
- 340.** A. Valachis, NP. Polyzos, V. Georgoulis, D. Mavroudis, D. Mauri: Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. *Gynecol Oncol* 117: 139-145, 2010.
- 341.** A.G. Pallis, K. Syrigos, A. Kotsakis, N. Karachaliou, A. Polyzos, V. Chandrinos, I. Varthalitis, Ch. Christophyllakis, A. Ardavanis, L. Vamvakas, N. Vardakis, Z. Saridaki, G. Samonis, S. Giassas, V. Georgoulis, S. Agelaki: Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients with advanced non-small cell lung cancer pre-treated with non-platinum-based chemotherapy: A multicenter randomized phase II study *Clinical Lung Cancer* 12: 100-105, 2011.
- 342.** E. Saloustros, N. Androulakis, L. Vamvakas, D. Mavroudis, V. Georgoulis: Favourable clinical course of patients experiencing bevacizumab-induced proteinuria. *Cases Reports in Oncology* 30: 4335-4342, 2010.
- 343.** A. Kotsakis, V. Georgoulis: Targeting epidermal growth factor receptor in the treatment of non-small cell lung cancer. *Expert Opin Pharmacoth* 11: 1-27, 2010.
- 344.** P. Vorkas, N. Poumpouridou, S. Agelaki, C. Krousis, V. Georgoulis, E. Lianidou: PIK3CA Hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. *J Mol Diagnostics* 12: 697-704, 2010.
- 345.** S. Baka, S. Agelaki, A. Kotsakis, M. Veslemes, P. Papakotoulas, M. Agelidou, A. Agelidou, E. Tsaroucha, G. Pavlaku, A. Gerogianni, N. Androulakis, L. Vamvakas, K. Kalbakis, D. Mavroudis, V. Georgoulis: Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. *Anticancer Res* 30: 3031-3038, 2010.
- 346.** A. G. Pallis, V. Chandrinos, G. Pavlaku, N. Xenidis, I. Varthalitis, N. Vardakis, L. Vamvakas, E. Kontopodis, M. Rovithi, V. Georgoulis: A multicenter phase I trial of

- metronomic oral Vinorelbine plus Cisplatin in patients with NSCLC. *Cancer Chem Pharm* 67: 1239-1245, 2011.
- 347.** N. Karachaliou, A. Polyzos, N. Kentepozidis, S. Kakolyris, N. Ziras, N. Vardakis, A. Kalykaki, G. Milaki, V. Georgoulis, N. Androulakis: A multicenter phase II trial with Irinotecan plus Oxaliplatin as first line treatment for inoperable/metastatic cancer of biliary tract. *Oncology* 78: 356-360, 2010.
- 348.** N. Xenidis, N. Vardakis I. Varthalitis S. Giassas E. Kontopodis N. Ziras I. Gioulbasanis G. Samonis K. Kalbakis V. Georgoulis: A Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Irinotecan as Second-Line Treatment of Patients with Refractory Small-Cell Lung Cancer. *Cancer Chem Pharm* 68(1):63-8, 2011.
- 349.** A. Polyzos, K. Kalbakis, N. Kentepozidis, S. Giassas, A. Kalykai, N. Vardakis, V. Bozionelou, E. Saloustros, E. Kontopodis, V. Georgoulis, D. Mavroudis: Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. *Cancer Chem Pharm* 68: 217-223, 2010.
- 350.** I. Gioulbasanis, V. E. Baracos, Z. Giannousi, A. Xyrafas, L. Martin, V. Georgoulis, D. Mavroudis: Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment (MNA) versus weight loss history. *Ann Oncol* 22: 835-841, 2011.
- 351.** A. Kotsakis, D. Hatzidaki, L. Vamvakas, N. Vardakis, A. Kalykaki, V. Bozionelou, N. Androulakis, K. Kalbakis, Z. Saridaki, V. Georgoulis, S. Agelaki: A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. *Anticancer Res* 30: 4335-4342, 2010.
- 352.** A. Kotsakis, S. Agelaki, N. Vardakis, G. Stathopoulos, L. Vamvakas, A. Kalykaki, N. Kentepozidis, E. Kontopodis, G. Sfakiotaki, D. Mavroudis, V. Georgoulis: A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. *Cancer Chemother Pharmacol* 68: 415-22, 2010.
- 353.** N. Vardakis, I. Messaritakis, C. Papadaki, G. Agoglossakis, M. Sfakianaki, Z. Saridaki, S. Apostolaki, I. Koutroubakis, M. Perraki, D. Hatzidaki, D. Mavroudis, V. Georgoulis, J. Souglakos: Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer (CRC). *Clin Cancer Res* 17: 165-173, 2011.
- 354.** AG. Pallis, S. Agelaki, A. Agelidou, I. Varthalitis, K. Syrigos, N. Kentepozidis, G. Pavlakou, A. Kotsakis, E. Kontopodis, V. Georgoulis: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line

- treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer. *BMC Cancer* 10: 633-641, 2010.
- 355.** G. Ioannidis, V. Georgoulas, J. Souglakos: Targeting VEGF-Biomarkers: A new age in personalized healthcare. *Forum Clin Oncol* 1(2): 62-73, 2010.
- 356.** N. Tselis, M. Ratka, HG. Vogt, C. Kolotas, M. Baghi, D. Baltas, G. Fountzilias, V. Georgoulas, H. Ackermann, N. Zamboglou: Hypofractionated accelerated CT-guided interstitial (192)Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. *Radiother Oncol* 98: 57-62, 2011.
- 357.** C. Papadaki, E. Tsaroucha, L. Kaklamanis, E. Lagoudaki, M. Trypaki, K. Tryfonidis, D. Mavroudis, E. Stathopoulos, V. Georgoulas, J. Souglakos: Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. *Br J Cancer* 104: 316-323, 2011.
- 358.** M. Spiliotaki, H. Markomanolaki, M. Mela, D. Mavroudis, V. Georgoulas, S. Agelaki: Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. *Lung Cancer* 73:158-65, 2011.
- 359.** A. Markou, A. Strati, N. Malamos, V. Georgoulas, ES. Lianidou: Molecular Characterization of Circulating Tumor Cells in Breast Cancer by a Liquid Bead Array Hybridization Assay. *Clin Chem* 57: 421-430, 2011.
- 360.** E. Saloustros, K. Tryfonidis, V. Georgoulas: Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. *Expert Opin Pharmacother.* 12: 851-863, 2011.
- 361.** Z. Saridaki, M. Tzardi, C. Papadaki, M. Sfakianaki, F. Pega, A. Kalikaki, E. Tsakalaki, M. Trypaki, I. Messaritakis, E. Stathopoulos, D. Mavroudis, V. Georgoulas, J. Souglakos: Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in  $\geq 2$  Line Cetuximab-Based Therapy of Colorectal Cancer Patients. *PLoS One* 6: e15980, 2011.
- 362.** M. Daskalakis, D. Mavroudis, E. Sanidas, S. Apostolaki, I. Askoxylakis, E. de Bree, V. Georgoulas, J. Melissas: Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. *Eur J Surg Oncol* 37: 404-410, 2011.
- 363.** K. Stylianou, E. Lioudaki, E. Papadimitraki, G. Kokologiannakis, N. Kroustalakis, C. Liotsi, K. Giannakakis, V. Georgoulas, E. Daphnis: Crescentic glomerulonephritis

- associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. *Nephrol Dial Transplant* 26: 1742-1745, 2011.
- 364.** AG. Pallis, A. Karampeazis, L. Vamvakas, N. Vardakis, A. Kotsakis, V. Bozionelou, A. Kalykaki, D. Hatzidaki, D. Mavroudis, V. Georgoulis. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. *Ann Oncol.* 2011 Nov;22(11):2448-55. Epub 2011 Mar 10.
- 365.** A. Karampeazis, L. Vamvakas, A. Agelidou, N. Kentepozidis, K. Chainis, V. Chandrinos, N. Vardakis, A. G. Pallis, Ch. Christophyllakis, V. Georgoulis: Docetaxel versus vinorelbine in elderly patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group randomized phase III study. *Clinical Lung Cancer* 12: 155-160, 2011.
- 366.** K. Krasagakis, M. Metaxari, M. Zervou, EN. Stathopoulos, J. Eberle, J. Kanitakis, V. Georgoulis, S. Krüger-Krasagakis, N. Tavernarakis, AD. Tosca: Identification of the M541L Sequence Variation of the Transmembrane KIT domain in Merkel Cell Carcinoma. *Anticancer Res* 31: 807-811, 2011.
- 367.** M. Kafousi, T. Vrekoussis, E. Tsentelierou, K. Pavlakis, I. Navrozoglou, V. Dousias, E. Sanidas, D. Tsiftsis, V. Georgoulis, EN Stathopoulos: Immunohistochemical Study of the Angiogenetic Network of VEGF, HIF1 $\alpha$ , VEGFR-2 and Endothelial Nitric Oxide Synthase (eNOS) in Human Breast Cancer. *Pathol Oncol Res.* 2012 Jan;18(1):33-41. doi: 10.1007/s12253-011-9413-8.
- 368.** M Chimonidou, A Strati, A Tzitzira, G Sotiropoulou, N Malamos, V Georgoulis, ES Lianidou: DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells. *Clin Chem* 57(8): 1169-77, 2011.
- 369.** M. Rovithi, AG. Pallis, A. Kalykaki, E. Lagoudaki, L. Giannikaki, EN. Stathopoulos, K. Relakis, V. Georgoulis: Small cell ovarian cancer in adolescents: report of two cases and review of the literature. *Case Report Med* 2011: 749516, 2011.
- 370.** I. Boukovinas, N. Androulakis, N. Kentepozidis, A. Polyzos, P. Papakotoulas, N. Ziras, A. Kotsakis, N. Vardakis, A. Karampeazis, V. Markos, A. Kostakopoulos, CA. Constantinides, G. Samonis, D. Mavroudis, V. Georgoulis: Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *Cancer Chemother Pharmacol.* 2012 Feb;69(2):351-6.

- 371.** E. Saloustros, K. Kalbakis, N. Vardakis, A. Kalykaki, G. Milaki, M. Rovithi, S. Agelaki, Z. Saridaki, V. Georgoulas, D. Mavroudis: Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. *Journal of BUON* 16: 215-218, 2011.
- 372.** A. Valachis, D. Mauri, NP, Polyzos, G. Chlouverakis, D. Mavroudis, V. Georgoulas: Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. *Breast*, Dec;20(6):485-90. Epub 2011 Jul 23.
- 373.** EK Vetsika, G. Konsolakis, D. Aggouraki, A. Kotsakis, E. Papadimitraki, S. Christou, J. Menez-Jamet, K. Kosmatopoulos, V. Georgoulas, D. Mavroudis: Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. EK Vetsika, G. Konsolakis, D. Aggouraki, A. Kotsakis, E. Papadimitraki, S. Christou, J. Menez-Jamet, K. Kosmatopoulos, V. Georgoulas, D. Mavroudis: Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. *Cancer Immunol Immunother.* 2012 Feb;61(2):157-68.
- 374.** A. Kotsakis, EK. Vetsika, S. Christou, D. Hatzidaki, N. Vardakis, D. Aggouraki, G. Konsolakis, V. Georgoulas, C. Christophyllakis, P. Cordopatis, K. Kosmatopoulos, D. Mavroudis: Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. *Ann Oncol.* 2012 Feb;23(2):442-9.
- 375.** I. Ioannidis, V. Georgoulas, J. Souglakos: How close are we to customizing chemotherapy in early non-small cell lung cancer? *Therapeutic Advances in Medical Oncology* 3: 185-205, 2011.
- 376.** AG. Pallis, I. Boukovinas, A. Ardavanis, I. Varthalitis, N. Malamos, V. Georgoulas, D. Mavroudis: A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. *Ann Oncol.* 2012 May;23(5):1164-9.
- 377.** T. Brodowicz, T. Ciuleanu, J. Crawford, M. Filipits, JR Fischer, V. Georgoulas, C. Gridelli, FR. Hirsch, J. Jassem, P. Kosmidis, M. Krzakowski, C. Manegold, JL. Pujol, R. Stahel, N. Thatcher, J. Vansteenkiste, C. Minichsdorfer, S. Zöchbauer-Müller, R. Pirker, CC. Zielinski; for the Central European Cooperative Oncology Group (CECOG): Third

- CECOG consensus on the systemic treatment of non-small-cell lung cancer. *Ann Oncol.* 2012 May;23(5):1223-9.
- 378.** E. Saloustros, M. Perraki, S. Apostolaki, G. Kallergi, A. Xyrafas, K. Kalbakis, S. Agelaki, A. Kalykaki, V. Georgoulis, D. Mavroudis: Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. *Breast Cancer Res* 13(3): R60, 2011.
- 379.** Z. Giannousi, I. Gioulbasanis, A.G. Pallis, A. Xyrafas, D. Dalliiani, K. Kalbakis, V. Papadopoulos, D. Mavroudis, V. Georgoulis, CN. Papandreou: Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. *Support Care Cancer.* 2012 Aug;20(8):1823-9.
- 380.** A. Strati, A. Markou, C. Parisi, E. Politaki, D. Mavroudis, V. Georgoulis, E. Lianidou: Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. *BMC Cancer* 11(1): 422, 2011.
- 381.** PJ. Vlachostergios, I. Gioulbasanis, K. Kamposioras, P. Georgoulis, VE. Baracos, S. Ghosh, E. Maragouli, V. Georgoulis, CN. Papandreou: Baseline Insulin-Like Growth Factor-I Plasma Levels, Systemic Inflammation, Weight Loss and Clinical Outcome in Metastatic Non-Small Cell Lung Cancer Patients. *Oncology* 81: 113-118, 2011.
- 382.** EK. Vetsika, E. Papadimitraki, D. Aggouraki, G. Konsolakis, ME. Mela, A. Kotsakis, S. Christou, S. Patramani, M. Alefantinou, A. Kaskara, C. Christophyllakis, K. Kosmatopoulos, V. Georgoulis, D. Mavroudis: Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients. *J Immunother* 34: 641-50, 2011.
- 383.** AG. Pallis, V. Georgoulis: Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. *Lung Cancer.* 2012 Mar;75(3):269-74.
- 384.** AG. Pallis, A. Voutsina, N. Kentepozidis, S. Giassas, P. Papakotoulas, S. Agelaki, K. Tryfonidis, A. Kotsakis, L. Vamvakas, N. Vardakis, V. Georgoulis: A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* 2012 Mar;13(2):129-35.
- 385.** Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, Margioris AN, Papandreou CN, Mavroudis D, Georgoulis V. Baseline Plasma Levels of Interleukin-8 in Stage IV Non-Small-Cell Lung Cancer Patients: Relationship With Nutritional Status and Prognosis. *Nutr Cancer.* 2012 Jan;64(1):41-7.

- 386.** Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulas V, Polyzos A. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). *Br J Cancer*. 2012 Jan 31;106(3):453-9. doi: 10.1038/bjc.2011.594.
- 387.** D.P. Kofteridis, A. Valachis, E. Koutsounaki, S. Maraki, E. Mavrogeni, F.N. Economidou, D. Dimopoulou, K. Kalbakis, V. Georgoulas and G. Samonis. Skin and Soft Tissue Infections in Patients with Solid Tumours. *The ScientificWorld Journal* Volume 2012, Article ID 804518, 6 pages doi:10.1100/2012/804518.
- 388.** Karachaliou N, Kouroussis C, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulas V, Mavroudis D. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2012 Feb 17. [Epub ahead of print].
- 389.** Georgoulas V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. *Ann Oncol*. 2012 Feb 29. [Epub ahead of print]
- 390.** Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J. ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol*. 2012 Apr;7(4):663-71.
- 391.** Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulas V. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. *Lung Cancer*. 2012 Mar 12. [Epub ahead of print]
- 392.** Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulas V. The Glasgow Prognostic Score (GPS) predicts

- toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. *Lung Cancer*. 2012 Apr 30. [Epub ahead of print]
- 393.** Kotsakis A, Harasymczuk M, Schilling B, Georgoulas V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. *J Immunol Methods*. 2012 Apr 13. [Epub ahead of print]
- 394.** Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulas V. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. *Cancer Chemother Pharmacol*. 2012 Jun 3. [Epub ahead of print]
- 395.** Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulas V. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. *Br J Cancer*. 2012 Jun 5;106(12):1917-25. doi: 10.1038/bjc.2012.202.
- 396.** Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulas V, Mavroudis D. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2012 Jun 6. [Epub ahead of print]
- 397.** Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulas V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. *Mod Pathol*. 2012 Aug 31. doi: 10.1038/modpathol.2012.150. [Epub ahead of print]
- 398.** VF Fragoulakis, AG Pallis, DK Kaitelidou, NM Maniadakis, VG Georgoulas. Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis. *Lung Cancer: Targets and Therapy* 2012;3 43–51
- 399.** Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulas V, Lianidou E. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. *Clin Biochem*. 2012 Sep 21. doi:pii: S0009-9120(12)00545-0. 10.1016/j.clinbiochem.2012.09.015. [Epub ahead of print]
- 400.** Dimitrakopoulos L, Vorkas PA, Georgoulas V, Lianidou ES. A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative



- determination of CST6 promoter methylation in clinical samples. *BMC Cancer*. 2012 Oct 22;12:486. doi: 10.1186/1471-2407-12-486.
- 401.** Chimonidou M, Strati A, Malamos N, Georgoulas V, Lianidou ES. SOX17 Promoter Methylation in Circulating Tumor Cells and Matched Cell-Free DNA Isolated from Plasma of Patients with Breast Cancer. *Clin Chem*. 2012 Nov 7. [Epub ahead of print]
- 402.** Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulas V, Souglakos J. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. *Br J Cancer*. 2012 Dec 4;107(12):1932-7. doi: 10.1038/bjc.2012.509. Epub 2012 Nov 20.
- 403.** Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulas V. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. *Br J Cancer*. 2013 Jan 17. doi: 10.1038/bjc.2012.597. [Epub ahead of print]
- 404.** Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiririou Z, Samonis G, Georgoulas V. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group. *Cancer Chemother Pharmacol*. 2013 Mar;71(3):605-12.
- 405.** Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulas V, Agelaki S. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. *J Chemother*. 2013 Feb;25(1):49-55.
- 406.** Vlachostergios PJ, Gioulbasanis I, Ghosh S, Tsatsanis C, Papatsibas G, Xyrafas A, Hatzidaki E, Vasiliou C, Kamposioras K, Agelaki S, Margioris AN, Nasi D, Georgoulas V, Papandreou CN. Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer. *Clin Transl Oncol*. 2013 Mar 5. [Epub ahead of print]
- 407.** Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulas V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. Prediction of survival benefits from

- progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. *BMJ Open*. 2013 Mar 13;3(3).
- 408.** Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, Anagnostopoulos A, Athanasiadis A, Stoltidis D, Georgoulas V, Souglakos J. Postoperative Treatment With Docetaxel, Cisplatin, and Capecitabine (DCX) and Chemoradiotherapy (CRT) With Capecitabine for Resected Gastric Adenocarcinoma. *Am J Clin Oncol*. 2013 Apr 3. [Epub ahead of print]
- 409.** Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulas V. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. *Cancer Chemother Pharmacol*. 2013 Jul;72(1):45-51.
- 410.** Georgoulas V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C. A multicenter randomized phase IIb efficacy study of vx-001, a Peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. *Clin Lung Cancer*. 2013 Jul;14(4):461-5.
- 411.** Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulas V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. *Cancer*. 2013 May 9. doi: 10.1002/cncr.28132. [Epub ahead of print]
- 412.** Chimonidou M, Kallergi G, Georgoulas V, Welch DR, Lianidou ES. Breast Cancer Metastasis Suppressor-1 promoter methylation in primary breast tumors and corresponding Circulating Tumor Cells. *Mol Cancer Res*. 2013 Jun 6. [Epub ahead of print]
- 413.** Lianidou ES, Mavroudis D, Georgoulas V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. *Br J Cancer*. 2013 Jun 25;108(12):2426-32.
- 414.** Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, Georgoulas V, Agelaki S. Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients. *Mol Cancer Ther*. 2013 Jun 18. [Epub ahead of print]
- 415.** Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulas V, Mavroudis D. Excision-repair-cross-complement-1 protein as a prognostic factor in

- patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. *Lung Cancer*. 2013 Nov;82(2):324-9. doi: 10.1016/j.lungcan.2013.08.001. Epub 2013 Aug 11.
- 416.** Matikas A, Vardakis N, Souglakos J, Georgoulas V. A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation. *BMJ Case Rep*. 2013 Sep 17;2013. doi:pii: bcr2013200502. 10.1136/bcr-2013-200502.
- 417.** Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J. Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. *PLoS One*. 2013 Sep 13;8(9):e74611. doi: 10.1371/journal.pone.0074611.
- 418.** Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulas V, Mavroudis D; Hellenic Oncology Research Group (HORG). A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. *Breast*. 2013 Dec;22(6):1171-7.
- 419.** Georgios Ioannidis, John Souglakos & Vassilis Georgoulas. Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy. *Lung Cancer Management* August 2013, Vol. 2, No. 4, Pages 281-293
- 420.** Markou A, Yousef GM, Stathopoulos E, Georgoulas V, Lianidou E. Prognostic Significance of Metastasis-Related microRNAs in Early Breast Cancer Patients with a Long Follow-up. *Clin Chem*. 2013 Oct 16. [Epub ahead of print]
- 421.** Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J. BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome. *PLoS One*. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013.
- 422.** Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulas V. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. *Cancer Chemother Pharmacol*. 2014 Feb 4. [Epub ahead of print]

- 423.** Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, Kalykaki A, Kalbakis K, Samonis G, Georgoulas V. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG). *Cancer Chemother Pharmacol.* 2014 Apr;73(4):819-25.
- 424.** Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, Georgoulas V, Lianidou ES. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. *Br J Cancer.* 2014 Apr 15;110(8):2054-62.
- 425.** Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, Gilpin C, Castellsagué E, Silva-Smith R, Plourde F, Wu M, Saskin A, Arseneault M, Karabakhtsian RG, Reilly EA, Ueland FR, Margiolaki A, Pavlakis K, Castellino SM, Lamovec J, Mackay HJ, Roth LM, Ulbright TM, Bender TA, Georgoulas V, Longy M, Berchuck A, Tischkowitz M, Nagel I, Siebert R, Stewart CJ, Arseneau J, McCluggage WG, Clarke BA, Riazalhosseini Y, Hasselblatt M, Majewski J, Foulkes WD. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. *Nat Genet.* 2014 Mar 23. doi: 10.1038/ng.2931. [Epub ahead of print]
- 426.** Fostira F, Tsoukalas N, Konstantopoulou I, Georgoulas V, Christophyllakis C, Yannoukakos D. A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype. *Case Rep Genet.* 2014;2014:875029.
- 427.** Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulas V, Souglakos J. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *BMC Cancer.* 2014 Apr 22;14:277.
- 428.** Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulas V. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *Cancer Chemother Pharmacol.* 2014 Jun 15. [Epub ahead of print]

- 429.** Saridaki Z, Souglakos J, Georgoulas V. Prognostic and predictive significance of MSI in stages II/III colon cancer. *World J Gastroenterol.* 2014 Jun 14;20(22):6809-6814.
- 430.** Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulas V, Stathopoulos E, Mavroudis D. Detection of Circulating Cytokeratin-19 mRNA-Positive Cells in the Blood and the Mitotic Index of the Primary Tumor Have Independent Prognostic Value in Early Breast Cancer. *Clin Breast Cancer.* 2014 Jun 2. pii: S1526-8209(14)00081-0. doi: 10.1016/j.clbc.2014.04.001. [Epub ahead of print]

**II/ΣΥΜΜΕΤΟΧΗ ΣΕ ΔΙΕΘΝΕΙΣ ΣΥΝΕΡΓΑΤΙΚΕΣ ΜΕΛΕΤΕΣ**

1. Consensus on medical treatment of non-small cell lung cancer. *Lung Cancer* 38: S3-S7, 2002.
2. C. Punt, A. Nagy, JY. Douillard, A. Figer, T. Skovsgaard, J. Monson, C. Barone, G. Fountzilias, H. Riess, E. Moylan, D. Jones, J. Dethling, J. Colman, L. Coward, S. MacGregor: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. *The Lancet* 360: 671-677, 2002.
3. P. Goss, J. Ingle, S. Martino, N. Robert, H. Muss, M. Piccart, M. Castiglione, D. Tu, L. Shepherd, K. Pritchard, R. Livingston, N. Davidson, L. Norton, E. Perez, J. Abrams, P. Therasse, M. Palmer, J. Pater: A randomized trial of letrozole in postmenopausal women after five of tamoxifen therapy for early-stage breast cancer. *N Engl J Medicine* 349: 1793-1802, 2003.
4. F. Fossella, J. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, E. Kaukel, K. mattson, R. Ramlau, A. Szczesna, P. Fidias, M. Millward, Ch. Belani: Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 study group. *J Clin Oncol* 21: 3016-3024, 2003.
5. The International Adjuvant Lung cancer Trial Collaborative Group: Cisplatin-Based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: *N Engl J Med* 350: 351-360, 2004.
6. MJ. Piccart-Gebhart: New stars in the sky of treatment for early breast cancer. *N Engl J Medicine* 350: 1140-1092, 2004.
7. Ch. Coombes, Em. Hall, L. Gibson, R. Paridaens, J. Jassem, Th. Delozier, S. Jones, I. Alvarez, G. Bertelli, O. Ortrmann, A. Coates, E. Bajetta, D. Doswell, R. Coleman, L. Fallowfield, E. Mickiewicz, J. Andersen, P. Lonning, G. Cocconi, A. Stewart, N. Stuart, C. Snowdon, M. Carpentieri, G. Massimini, J. Bliss for the Intergroup Exemestane Study. *N Engl J Medicine* 350: 1081-1092, 2004.
8. Ronald H. Blum: Adjuvant Chemotherapy for Lung Cancer – A New Standard of Care. *N Engl J Med* 350: 404-405, 2004.
9. MER O' Brien, N. Wigler, M. Inbar, et al, on behalf of the CAELYX Breast Cancer Group: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated

- liposomal doxorubicin HCl (CAELYX<sup>TM</sup>/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol* 15: 440-449, 2004.
10. A. Bamias, G. Aravantinos, C. Deliveliotis, et al: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group: *J Clin Oncol* 22: 220-228, 2004.
  11. The International Adjuvant Lung Cancer Trial (IALT) Collaborative Group: A randomized trial of cisplatin-based adjuvant chemotherapy in 1,867 patients with resected non-small lung cancer. *New Engl J Med* 350: 351-360, 2004.
  12. A. Brunello, U. Basso, C. Pogliani, A. Jirinno, C. Ghiotto, H. Koussis, F. Lumachi, M. Iacobone, L. Vamvakas, S. Manfardini: Adjuvant chemotherapy for elderly ( $\geq 70$  years) with early high-risk breast cancer: a retrospective analysis of 260 patients. *Ann Oncol* 16: 1276-1282, 2005.
  13. C.C. Zielinski, M. Krainer, R. Pirker, et al: Consensus on medical treatment of non-small lung cancer-update 2004. *Lung Cancer* 50: 129-137, 2005.
  14. M. Martin, T. Pienkowski, J. Mackey, et al: Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med* 352: 2302-2313, 2005.
  15. E. Van Cutsem, B. Nordlinger, R. Adam, CH. Kohne, C. Pozzo, G. Poston, M. Ychou, P. Rougier on behalf of European Colorectal Metastases Treatment Group: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. *Eur J Cancer* 42: 2212-2221, 2006.
  16. JY. Douillard, R. Rosell, M. De Lena, F. Carpagnano, R. Ramlau, J L. Gonz ales-Larriba, T. Grodzki, J. Rodrigues Pereira, A. Le Groumellec, V. Lorusso, C. Clary, A. J. Torres, J. Dahabreh, PJ. Souquet, J. Astudillo, P. Fournel, A. Artal-Cortes, J. Jassem, L. Koubkova, P. His, M. Riggi, P. Hurteloup: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *The Lancet Oncology* 7: 719-727, 2006.
  17. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I.G.H. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R.J. Motzer for the Global ARCC Trial: Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. *N Engl J Med* 356: 2271-2281, 2006.

18. M. Di Maio, P. Chiodini, V. Georgoulas, D. Hatzidaki, K. Takeda, F.W. Wachtters, V. Gebbia, E.F. Smit, A. Morabito, C. Gallo, F. Perrone, C. Gridelli: Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second line treatment of advanced non-small cell lung cancer *J Clin Oncol* 27: 1836-1843, 2009
19. Krzakowski M; DYNEPO Oncology Study Group: Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy. *Clin Oncol (R Coll Radiol)* 20: 705-713, 2008.
20. R. Arriagada, A. Dunant, JP. Pignon, B. Bergman, M. Chabowski, D. Grunenwald, M. Kozlowski, C. Le Pechoux, R. Pirker, MI. Sathler, Pinel, M. Tarayre, T. Le Chevalier: Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. *J Clin Oncology*, 2009.
21. E. Van Cutsem, F. Rivera, S. Berry, A. Kretschmar, M. Michael, M. Dibartolomeo, MA. Mazier, JL. Canon, V. Georgoulas, M. Peeters, J. Bridgewater, D. Cunningham D; on behalf of the First BEAT investigators: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Ann Oncol* 20: 1842-1847, 2009.
22. M. Di Maio, N. Lama, A. Morabito, EF. Smit, V. Georgoulas, K. Takeda, E. Quoix, D. Hatzidaki, FM. Wachtters, V. Gebbia, CM. Tsai, C. Camps, W. Schuette, P. Chiodini, MC. Piccirillo, F. Perrone, C. Gallo, C. Gridelli: Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. *Eur J Cancer* 46: 735-743, 2010
23. D. Slamon, W. Eiermann, N. Robert, T. Pienkowski, M. Martin, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pinter, V. Valero, MC. Liu, G. Sauter, G. von Minckwitz, F. Visco, V. Bee, M. Buyse, B. Bendahmane, I. Tabah-Fisch, MA. Lindsay, A. Riva, J. Crown; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med* 365: 1273-1283, 2011.
24. Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). *Ann Oncol*. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19.



### III/ΓΡΑΜΜΑΤΑ ΣΤΟΝ ΕΚΔΟΤΗ

1. V. Georgoulas, N. Papanikolaou, D. Loukopoulos, G. Fessas: The liver in hairy cell leukemia. *Ann Int Med* 93: 380-381, 1980.
2. V. Georgoulas, D. Fountouli, A. Karvela-Agelaki, G. Komis, E. Malliaraki-Pinetidou et al. HIV-1 and HIV-2 double infection in Greece. *J Int Med* 108: 155, 1988.
3. M. Allouche, V. Georgoulas, C. Varela-Millot, M. Itzaki, J.L. Misset, C. Jasmin: Prognostic value of spontaneous peripheral blood T colony-forming cells in T-cell acute lymphoblastic leukemia in complete remission: An update evaluation. *Brit J Haemat* 72: 291, 1989.
4. N. Zoumbos, A. Symeonidis, A. Kourakli, P. Katevas, P. Matsoukas, M. Perraki, V. Georgoulas: Increased levels of soluble Interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes. *Blood* 75: 413, 1991.
5. F. Graziano, S. Cascinu, V. Georgoulas: Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? *J Clin Oncol*: 18: 445-446, 2000.
6. H. Satoh, K. Sekizawa, J.P. Van Meerbeek, C. Legrand, R.J. Van Klaveren, G. Giaccone, V. Georgoulas, I.G. Vlachonikolis: Chemotherapy for non-small-cell lung cancer. *Lancet* 358: 1270-1272, 2001.
7. S. Agelaki, E. Karyda, Ch. Kouroussis, A. Ardavanis, K. Kalbakis, K. Malas, N. Malamos, A. Alexopoulos, E. Tselepatiotis, V. Georgoulas: Gemcitabine plus Irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: A multicenter phase II study. *Oncology* 64: 477-478, 2003.
8. C. Lionis, G. Samoutis, Ch. Kouroussis, M. Trigoni, V. Georgoulas: Teaching cancer management to primary care health staff: the first experiences gained from Crete. *J Cancer Educ*. Spring 20: 6-7, 2005.
9. A. Pallis, V. Georgoulas: Ethics in medical publishing: a “burning” issue. *Forum of Clin Oncology* 1(3): 9-10, 2010.
10. N. Karachaliou, E. Saloustris, L. Vamvakas, D. Mavroudis, V. Georgoulas: Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. *Ann Oncol* 21: 1729-1730, 2010.
11. Karampeazis A, Georgoulas V. Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2012 Apr 19. [Epub ahead of print]

#### IV/ PROCEEDINGS ΣΥΝΕΔΡΙΩΝ/ΒΙΒΛΙΩΝ

##### ΕΛΛΗΝΙΚΑ

1. Δ. Καμαρούλιας, Κ. Χαρώνης, Ι. Αντωνάκου, Β. Γεωργούλιας: Εισρόφηση ξένου σώματος υποδυθείσα βρογχογενές νεόπλασμα: Τόμος στην Μνήμη του Ν.Τσαγγάρη σελ. 81:1978.
2. Α. Μητρόπουλος, Γ. Βεζύρογλου, Π. Δημητριάδης, Γ. Αποστολάκης, Β. Γεωργούλιας, Ι. Ζέρβας: Αντιγόνα ιστοσυμβατότητας επί ρευματοειδούς αρθρίτιδας. Πρακτικά 4ου Πανελληνίου Ιατρικού Συνεδρίου σελ.853,1978.
3. Β. Γεωργούλιας: Κλινική αξία της in vitro καλλιέργειας των προγονικών λευχαιμικών κυττάρων. Εξελίξεις και προοπτικές στην έρευνα του καρκίνου, Γ.Φούντζηλας σελ.179-197, 1989.
4. Β. Γεωργούλιας: Διάγνωση της μόλυνσης HIV. Τόμος Εθν. Επιτροπής AIDS σελ. 75,1990.
5. Β. Γεωργούλιας: Σύγχρονα επιδημιολογικά και βιολογικά χαρακτηριστικά της μόλυνσης HIV. Εκδοση Ελληνικής Οφθαλμολογικής Εταιρείας, 1992.
6. Μ. Σμυρλάκη-Θεοδωροπούλου, Ν. Μαλλιαράκη, Δ. Τσατσάκη, Σ. Κωτσάκη, Ε. Μαλλιαράκη-Πινετίδου, Β. Γεωργούλιας: Συσχέτιση in vitro πολλαπλασιασμού του HIV και της γενετικής του ανάλυσης με γονιδιακό πολλαπλασιασμό. 5<sup>ο</sup> Πανελλήνιο Συνέδριο Ιολογίας, 1992.
7. Β. Γεωργούλιας: Θεραπευτική αντιμετώπιση του καρκίνου του μαστού σταδίου Ι. Πρακτικά Συμποσίου Ακτινοθεραπευτικής Ογκολογίας, Κρήτη, 1994.
8. Β. Γεωργούλιας: Η μη χειρουργική αντιμετώπιση των σαρκωμάτων των μαλακών μορίων: Πρακτικά 5ου Πανελληνίου Μετεκπαιδευτικού Σεμιναρίου Γεν. Χειρουργικής, 1994.
9. Β. Γεωργούλιας: Διαγνωστική και χημειοθεραπευτική αντιμετώπιση των νεοπλασμάτων του μεσοθωρακίου. «Θέμα Παθολογίας-Ογκολογίας» Εκδ. ΕΟΠΕ, 1996.
10. Β. Γεωργούλιας: Απόπτωση και καρκίνος. Πανελλήνιο Συνέδριο Ακτινοθεραπευτικής Ογκολογίας, 1996.
11. Β. Γεωργούλιας, Χ. Κουρούσης: Η προεγχειρητική χημειοθεραπεία (κύρια ή εισαγωγής) στο χειρουργήσιμο καρκίνο του μαστού. Ελληνική Χειρουργική 69(6): 573-581, 1997.
12. Β. Γεωργούλιας, Μ. Τζωρτζακάκης: Αντιική θεραπεία στο σύνδρομο της επίκτητης ανοσολογικής ανεπάρκειας. Βασικές Αρχές Θεραπείας του Καρκίνου, Θεσσαλονίκη 1997.
13. Β. Γεωργούλιας: Χημειοθεραπεία του μη-μικροκυτταρικού καρκίνου του πνεύμονος. Πρωτοπαθής καρκίνος του πνεύμονα, Μετεκπαιδευτικό Σεμινάριο της Ελληνικής Πνευμονολογικής Εταιρείας σελ. 84-95.

14. Α. Πάλλης, Δ. Μαυρουδής, Β. Γεωργούλιας. Οι στοχευτικοί παράγοντες στην Ογκολογία. Στο βιβλίο των Γ. Φούντζηλα και Β. Μπαρμπούνη, Βασικές Αρχές Θεραπείας του Καρκίνου, σελ. 833-873 University Studio Press, 2006.

## ΞΕΝΟΓΛΩΣΣΑ

1. J. Zervas, J. Apostolakis, V. Georgoulis, A. Argyriou, A. Vareltzidis, Ph. Kaklamanis: HLA antigens and psoriasis-psoriatic arthritis. Proc. 1st Helleno-Yugoslav Congress of Rheumatology, p81-84, 1978.
2. J. Zervas, V. Georgoulis, J. Apostolakis, A. Michalakis, Ph. Kaklamanis, Ph.Fessas: The distribution of HLA antigens in patients with systemic lupus erythematosus. Proc. 1<sup>st</sup> Helleno-Yugoslav Congress of Rheumatology. p61-63 1978.
3. V. Georgoulis, C. Jasmin, F. Amesland: In vitro sensitivity of human Myeloblast colony-forming cells (CFU-ML) to anthracyclines, neoathramycin and Mitoxantrone. Proc. 13th International Congress of Chemotherapy, p 14.4/3, 1983.
4. V. Georgoulis, M. Allouche, C. Jasmin: Regulation of T-cell colony formation in the absence of added growth factors in patients with T-cell malignancies. Malignant lymphomas and Hodgkin's disease: Experimental and therapeutic advances. F. Cavalli, G. Bonadonna and M. Rozenzweig, eds, Martinus Nijhoff Publ, p: 57, 1985.
5. C. Jasmin, J.G. Judde, V. Georgoulis, F. Smadja-Joffe, H.F. Poupon: Models for adjuvant treatment. Edit. S.Jones, S.Salmon: Adjuvant therapy of Cancer, IV, Grune and Stratton, p:35, 1984.
6. V. Georgoulis, M. Allouche, C. Kosmatopoulos, C. Jasmin: Study of the T-cell colony-forming cell (T-CFC) proliferation in patients with T-cell malignancies. Leukemia. Recent advances in Biology and Treatment. Ed. Alan R.Liss Inc.p:505, 1985.
9. Y. Lunardi-Iskandar, V. Georgoulis, D. Klatzmann, P. Meyer, W. Rozenbaum, J.C. Gluckmann and C. Jasmin: Etude des precurseurs lymphocytaires T(T-CFC) chez des malades atteints du SIDA. Implications physiopathologiques Ed.R.Zittoun, Publ, Doin, Paris, Syndrome Immuno-deficitaire Acquis p:175, 1985.
10. C. Jasmin, M.F. Poupon, F. Smadja-Joffe, M.C. Bousse-Kerdiles, V. Georgoulis, M. Allouche, J.G. Judde: Tumor stem cells and their ecosystem: Therapeutic implications of a new concept. R and B Symposium, Local Immunity in cancer Edition E.Macher and Sorg.Regensberg and Biermann Publ., Munchen p: 114, 1986.

11. M. Allouche, V. Georgoulas and C. Jasmin: Involvement of the interleukin 2/ interleukin 2-receptor system in the pathophysiology of human acute lymphoblastic leukemias of T and B-cell origin. In Neo-adjuvant chemotherapy. Ed. C.Jacquillat. Co-edited by INSERM and John Libbey. Collogue INSERM: 169, p889, 1988.
12. C. Jasmin, V. Georgoulas and C. Boucheix: Leukemic stem cells and the chemocurability of human leukemia and lymphoma. In Neo-adjuvant chemotherapy. Et C.Jacgullat. Co-edited by INSERM and John Libbey. Collogue INSERM 169, p31,1988.
13. M. Theodoropoulou, E. Spanakis, N. Malliarakis, A. Karvela, D. Fountouli, E. Malliaraki-Pinetidou, V. Georgoulas: Antibodies against HIV gag-encoded proteins:A latent or an abortive infection with an HIV variant. In Molecular Biology of human retroviruses and their interactions. Ed. H.Rubsamen-Waigmann. GSH Journal 1:1,1990.
14. Y. Sahraoui, A. Ammar, Y. Lunardi-Iskandar, M. Perraki, V. Georgoulas: Abnormalities of Interleukin 2 receptor chains in HIV infection. In «Immumology of HIV infection» Ed. G.Janossy, Springer-Verlag p:157, 1992.
13. S. Kakolyris, G. Samonis, P. Toloudis, C. Kalmpakis, S. Agelaki, E. Kirlaki, G. Papadakis, A. Xilouris, V. Georgoulas: Continuous oral etoposide administration as treatment for non-small cell lung carcinoma. Proc. 1st Intern. Congress for Lung Cancer p:583, 1994.
14. V. Georgoulas: Biologic Considerations of renal cell carcinoma. ESO Course, 13-15 June 1996, Athens, Greece.
15. G. Samonis, S. Maraki, A. Georgiladakis, Ch. Kouroussis, V. Georogulias: New fungal infection in cancer patients. Proceedings of the 2<sup>nd</sup> Balcan Congress on Lung Cancer, Crete 9-13 November, pp 715-718, 1996.
16. N. Androulakis, Ch. Kouroussis, S. Kakolyris, P. Heras, G. Maltezakis, L. Vamvakas, S. Schiza, S. Agelaki, G. Metaxaris, J. Vlachonikolis, D. Hatzidaki, G. Samonis and V. Georgoulas: First line treatment of non-small cell lung carcinoma (NSCLC) with docetaxel and cis-platin: preliminary results of a phase II study. Proceedings 2<sup>nd</sup> International Congress on Lung Cancer, Crete 9-13 November, pp 661-667, 1996.
17. S. Koukouraki, A. Giatromanolaki, J. Damilakis, J. Skarlatos, N. Karkavitsas, C. Kourakos, V. Georgoulas, Ch. Kouroussis and M. Koukourakis: 99mTc-sestamibi radionuclide excretion rate in lung cancer: possible implications in predicting multi-drug resistance. Proceedings 2<sup>nd</sup> International Congress on Lung Cancer, pp 539-543, 1996.
18. Ch. Kouroussis, N. Androulakis, P. Heras, L. Vamvakas, G. Metaxaris, J. Souglakos, F. Vlastos, M. Dimadi, A. Vossos, P. Aravosita, Th. Georgopoulou, A. Papandreou, D.

- Hatzidaki, Em. Papadakis and V. Georgoulas: Monotherapy with docetaxel in previously treated patients with advanced non-small cell lung carcinoma. Proceedings 2<sup>nd</sup> International Congress on Lung Cancer, pp 571-574, 1996.
19. Ch. Kouroussis, N. Androulakis, S. Kakolyris, L. Vamvakas, P. Heras, G. Metaxaris, G. Maltezakis, G. Chalkiadakis, J. Vlachonikolis, D. Hatzidaki, G. Samonis and V. Georgoulas: First line treatment of non-small cell lung carcinoma (NSCLC) with docetaxel and vinorelbine: A phase II study. Proceedings 2<sup>nd</sup> International Congress on Lung Cancer, pp 673-679, 1996.
  20. V. Georgoulas, Ch. Kouroussis, S. Kakolyris: Quality of life: The experience of an Oncology Unit functioning in a rural Greek area: In Cancer, AIDS and Quality of Life, Ed. J.Levy et al, Plenum Press, NY, pp97-100, 1997.
  21. V. Georgoulas, J. Crown: Proceedings of a Satellite Symposium to the 23rd European Society of Medical Oncology, Athens, Greece, 6-10 November 1998: Increasing options in cancer therapy: current status and future prospects. *Anti-Cancer Drugs* 10(1): S1-S3, 1999.
  22. V. Georgoulas: Docetaxel/cisplatin versus docetaxel/gemcitabine as front-line treatment of advanced non-small-cell lung cancer: Preliminary results of a multicenter randomized trial. *Cancer Conference Highlights* 3(11): 5-7, 1999.
  23. G.F. Samelis, P. Papacostas, G.P. Stathopoulos, V. Georgoulas, N. Androulakis, Ch. Kouroussis, S. Kakolyris, K. Kalbakis, E. Lydaki, E. Sarra, N. Tsavaris, K. Genatas and Ch. Papadimitriou: Second line treatment of locally advanced and metastatic pancreatic cancer with Docetaxel and Gemcitabine: A phase II trial of the Greek Cooperative Group for pancreatic cancer. Proceedings 2<sup>nd</sup> Balkan Congress of Oncology, September 10-14 Izmir, Turkey, pp377-380, 1998.
  24. V. Georgoulas: A multicenter phase II trial of docetaxel and gemcitabine in untreated patients with non-small-cell lung cancer. *Physicians Education Resource* (υπό δημοσίευση).
  25. V. Georgoulas: Micrometastatic disease in breast cancer. ESO Course: From the molecular biology to the bedside oncology, 4-6 June 1998, Thessaloniki, Greece.
  26. V. Georgoulas: Commentary on "Sequential Chemotherapy: Rationale and Clinical Trial design in advanced non-small-cell carcinoma, *Clinical Lung Cancer*, November 1999, pp131.

27. V. Georgoulas: Innovations in chemotherapy of colorectal cancer. ESO Course: Advances and controversies in Surgical Oncology, 6-7 October 2000, Heraklion, Crete.
28. V. Georgoulas: The role of second line chemotherapy in advanced NSCLC. ESO Course: Thoracic Malignancies, 10-11 November 2000, Nicosia, Cyprus.
29. RL. Akehurst, T. Beinert, J. Crino, J. Debus, F. Eckersberger, J. Fischer, V. Georgoulas, C. Gridelli, FR. Hirsch, J. Jassem, P. Kosmidis, M. Krainer, M. Krzakowski, Ch. Manegold, J. Niklinski, R. Pirker, JL. Pujol, G. Scagliotti, N. Thatcher, M. Tonato, N. Van Zandwijk, CC. Zielinski, S. Zochbauer, M. Zwitter: Consensus on medical treatment of non-small cell lung cancer. *Lung Cancer* 38: S3-S7, 2002.
30. V. Georgoulas, A.G. Pallis: A patient with stage IV non-small cell lung cancer treated with cisplatin and docetaxel. *Case Studies In Lung Cancer* 1 (6): 1-7, 2002.
31. S. Agelaki and V. Georgoulas: Endocrine treatment of bone metastases. Jasmin Claude, Capanna Rodolfo, Coia Lawrence, Coleman Robert, Saillant Gerard (eds.) *Textbook of Bone Metastases* John Wiley & Sons 2005.
32. CC Zielinski, T. Beinert, J. Crawford, J.R. Fischer, V. Georgoulas, C. Gridelli, F. Hirsch, J. Jassem, Ch. Herold, P. Kosmidis, M. Krainer, M. Krzakowski, Ch. Manegold, R. Pirker, J.L. Pujol, N. Thatcher, S. Tomek, N. van Zandwijk, S. Zöchbauer-Müller, M. Zwitter: Consensus on medical treatment of non small cell lung cancer-update 2004. *Lung Cancer* 50: 129-137, 2005.
33. A. Pallis, S. Agelaki, V. Georgoulas: Treatment of NSCLC: Chemotherapy. Hansen: *Textbook of Lung Cancer*, 2<sup>nd</sup> Edition, pp 148-169.
34. N. Xenidis, M. Perraki, S. Kakolyris, D. Mavroudis, V. Georgoulas: Non-negative breast cancer: Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells. *Handbook on Methods of Cancer Diagnosis, Treatment and Prognosis. M.A. Hayat (ed)*, Springer, 2008.
35. A. G. Pallis, V. Georgoulas, D. Mavroudis: Advanced breast cancer: Treatment with docetaxel/Epirubicin. *Handbook on Methods of Cancer Diagnosis, Treatment and Prognosis. M.A. Hayat (ed)*, Springer, 2008.
36. A. Kotsakis, E. Kontopodis, and V. Georgoulas: Pros and Cons of Maintenance Therapy for Advanced Non- Small Cell Lung Cancer. *Emerging Cancer Therapeutics*, 3:1, 27-44, 2012.
37. A.G. Pallis, V. Georgoulas, S. Aggelaki: Chemotherapy Options for Advanced Non-Small Cell Lung Cancer. *Emerging cancer therapeutics*, ISSN 2151-4194 ; v. 3, issue 1

- 38.** A Kotsakis, N Kentepozidis and V Georgoulas. Metronomic Chemotherapy in Non-Small-Cell Lung Cancer. Metronomic Chemotherapy, 2014 (in press)

#### **X. ΔΙΑΤΡΙΒΕΣ**

- 1.** Β. Γεωργούλιας: Κύτταρα F στον ελληνικό πληθυσμό. Μελέτη με ανοσοφθορισμό, Ιατρική Σχολή Παν/μίου Αθηνών, 1981.
- 2.** V. Georgoulas: Approche physiopathologique de mecanismes de proliferation des cellules clonogeniques T chez les malades atteints des leucemies aigues lymphoblastiques et des lymphomes T. Diplome d' Etudes et de Recherches en Biologie Humaine (mention:Cancerologie Experimentale), Universitte Paris XI, 1984.

#### **ΣΥΣΤΑΤΙΚΕΣ ΕΠΙΣΤΟΛΕΣ:** Μπορούν να ζητηθούν από:

- 1.** Prof. Claude Jasmin: INSERM 268, Hopital Paul Brousse, 14-16 Av. P.V. Couturier, 94804 Villejuif, France.
- 2.** Prof. David Kahyat: Service d' Oncologie Medicale, Hopital Pitie-Salpetriere, 34 Bd de l' Hopital, 94013 Paris, France.
- 3.** Prof. Fred. Triebel: Service d'Immunologie, Institut Gustave Roussy, Rue Camille Desmoulins-94805 VILLEJUIF Cedex.
- 4.** Dr. F. Barre-Sinoussi: Directeur du Departement de Virologie, Institut Pasteur, 75014 Paris, France.
- 5.** Prof. J. L. Misset: Service des Maladies Sanguines et Tumorales, Hopital Paul Brousse, 14-16 Av. P.V. Couturier, 94804 Villejuif, France.
- 6.** Prof. P. Debre: Service d' Immunologie, Hopital Pitie-Salpetriere, 34 Bd de l' Hopital, 75013 Paris, France.
- 7.** Prof. G. Scagliotti: University of Turin, Via Berthollet 35, Torina 10125, Italy.
- 8.** Prof. T. Le Chevalier: Institut Gustave Roussy, 39 Rue Camille Desmoulins, Villejuif F-94805, France.
- 9.** Prof. J.P. Armand: Institut Gustave Roussy, 39 Rue Camille Desmoulins, Villejuif F-94805, France.
- 10.** Prof. Th. Lynch: Massachusetts General Hospital, 100 Blossom St Cax 2, Boston, MA 02114, USA.